#1:: BIOPHARMA The Art of Precision, The Science of Cure Pioneering personalized therapies for oncology and immunology DECEMBER 2023 NASDAQ:IMMX#2Disclaimer: Forward Looking Statements & Market Data ●●● S BIOPHARMA IMMIX This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, including statements regarding Immix Biopharma, Inc.'s (the "Company") strategy, future operations, future financial position, projected costs, prospects, plans, and objectives of management, are forward-looking statements. The words "anticipate,” “believe,” “continue,” “could,” “depends,” “estimate,” “expect,” “intend," "may," "ongoing," "plan," "potential," "predict," "project," "target," "should," "will," "would," and similar expressions are intended to identify forward- looking statements, although not all forward-looking statements contain these identifying words. The Company may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements. In addition, the forward-looking statements included in this presentation represent the Company's views as of the date of this presentation. The Company anticipates that subsequent events and developments will cause its views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of this presentation. This presentation also includes data from other approved therapies and in trials, which are generated from separate, independent studies and do not come from head- o-head analysis. Differences exist between study or trial designs and subject characteristics, and caution should be exercised when comparing data across studies sourced from publicly available sources. This presentation also contains estimates and other statistical data made by independent parties and by us relating to market size and growth and data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. In addition, projections, assumptions, and estimates of our future performance and the future performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk. These and other factors could cause results to differ materially from those expressed in the estimates made by the independent parties and by us. 2#3IMMX: Autoimmune CAR-T Company with 73 patients dosed to-date NXC-201 FDA Investigational New Drug (IND) Application Already Cleared 1 2 3 4 5 6 First CAR-T, NXC-201, in AL Amyloidosis Expanding into Additional Autoimmune indications First "single-day CRS" CAR-T NXC-201 n=73 patients across 11 peer-reviewed publications First CAR-T Overcoming Neurotoxicity IMX-110 - promising results in colorectal cancer with 30 patients dosed ● ● ● . ●●● IMMIX S BIOPHARMA 100% overall response rate in relapsed/refractory AL amyloidosis ($3bn market) No drugs approved in relapsed/refractory AL amyloidosis today (29,712 U.S. patient prevalence) BCMA CAR-Ts are not created equal: NXC-201 designed for high activity in AL Amyloidosis NXC-201 expanding into additional autoimmune indications - more than $25 bn combined annual market size NXC-201: first "single-day CRS" CAR-T (median day 1 onset) enables patients to return home 80% faster 95% overall response rate in relapsed/refractory multiple myeloma ($18bn market) 2 Presentations (1 Oral) at 2023 American Society of Hematology (ASH) 65th Meeting Mature dataset: American Society of Cell and Gene Therapy, Haematologica, other publications Precedents for open-label, single-arm FDA approvals at ~100 patient dataset - Carvykti, Abecma -10-20x potential increase in CAR-T addressable market through wider hospital availability -5x potential hospital per-bed revenue increase by reducing CAR-T hospitalization time Overcoming neurotoxicity allows expansion into: AL Amyloidosis, autoimmune, others 75% tumor shrinkage at 2 months in stage 4 MSS relapsed/refractory colorectal cancer ($27 billion market) 4 months median progression-free survival in soft tissue sarcoma ($3bn market), median 7 prior lines of therapy 3#4World-Class Team Leadership Board of Directors Members Scientific Advisory Board Members Ilya Rachman, MD, PhD Chief Executive Officer Cedars UCLA Health MEDICINE UIC COLLEGE OF Sinai AT CHICAGO Helen Adams, CPA Former Prometheus Biosciences Board Member Prometheus Deloitte. Biosciences Henry A. McKinnell, PhD Former Pfizer, Inc. Chief Executive Officer Pfizer MOODY'S Heather Landau, MD (MSK) Memorial Sloan Kettering Cancer Center Larry Norton, MD • SVP, Office of the President, Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering Cancer Center Gabriel Morris, BA Chief Financial Officer COLUMBIA UNIVERSITY Sachs Goldman IN THE CITY OF NEW YORK Director, Amyloidosis Program JOHN WAYNE CANCER INSTITUTE PrinceSat J . Founder, Sarcoma Oncology Research Center Sant Chawla, MD Johnson & Johnson THE UNIVERSITY OF TEXAS MD Anderson Cancer Center Magda Marquet, PhD ALMA Life Sciences ALTHEA Mary Sue Coleman, Ph.D Former Johnson & Johnson Board Member ALMA Life Sciences M VIKTIRAN AstraZeneca Suzanne Lentzsch, MD, PHD (Columbia) do COLUMBIA THE UNIVERSITY OF TEXAS MD Anderson Cancer Center Razelle Kurzrock, MD Chief, Oncology/ Hematology at UCSD School of Medicine UC San Diego School of Medicine Graham Ross, MBChB, FFPM Chief Medical Officer Roche gsk • KKR PRISMA Jane Buchan, PhD CEO, Martlet Asset Management J.P.Morgan Jeffrey H. Cooper, MBA Former BioMarin Chief Financial Officer BIOMARIN Director, Multiple Myeloma and Amyloidosis COLUMBIA UNIVERSITY HERBERT IRVING COMPREHENSIVE CANCER CENTER University Hospitals Bristol Drexel NHS Foundation Trust Galit Lahav, PhD Chair, Department of Systems Biology at Harvard Medical School HARVARD David Marks, MBBS, PhD Chief Medical Officer, Cell Therapy TECARTUS® Kite/Gilead NHS Pfizer KYMRIAH® Novartis MEDICAL SCHOOL Michaela Liedtke, MD (Stanford) RAYLIANT Gary Schiller, MD • UCLA Professor of Oncology UCLA Health ●●● IMMIX S BIOPHARMA Ave Gerhard Bauer Head of Cell Therapy Manufacturing Jason Hsu, PhD Founder & Chairman, Rayliant Global Advisors Stanford MEDICINE UCDAVIS American Society UNIVERSITY OF CUENT of Gene Cell Therapy research affiliates Edward J. Borkowski, CPA MBA Former Mylan Chief Financial Officer Mylan® Co-Director, Stanford Amyloid Center George Sledge, MD • Professor, former Chief, Oncology Division, Stanford Medicine Stanford MEDICINE 4#5N-GENIUS Platform Overview FIM 3 Key Elements Purpose-Built Cell Therapy Evidence Capture Engine + Relational Database Relating ImmixBio internal data to external to accelerate therapy design, manufacture, and preclinical Proprietary EXPAND technology Applied to multiple cell therapy indications, already utilized to create NXC-201, to potentially increase efficacy and tolerability Atomized, Novel Binding Scaffold Generation Engine Allows us to make the correct binding for every molecule N-GENIUS PLATFORM Allows ImmixBio To... Rapidly Pursue Additional Proven Target Indications ●●● IMMİX S BIOPHARMA Optimize CAR-T constructs across CAR-T indications to reduce toxicity without sacrificing efficacy to allow widespread adoption Identify specific relevant binder optimizations in each CAR-T candidate to increase or decrease binding affinity and avidly as appropriate 5#6Broad Autoimmune Disease Applicability of the ImmixBio N-GENIUS Platform Overcoming Neurotoxicity Enables Indication Expansion For NXC-201 CD19 CD20 ● ● ● BCMA Myasthenia Gravis Neuromyelitis Optica Spectrum Disorder Pemphigus Vulgaris Dermatomyositis Ulcerative Colitis Celiac disease Bone Marrow Pro-B Pre-B Immature B Naïve B Neurology Dermatology Gastroenterology Periphery I GC B Memory B Plasma blast I Bone Marrowi I Plasma cell I I I I Rheumatology Hematology Nephrology Other diseases AL Amyloidosis, Multiple Myeloma (3-days hospital instead of 14-days) Overcoming neurotoxicity ●●● S IMMIX BIOPHARMA Systemic Lupus Erythematosus Rheumatoid Arthritis IgA nephropathy IgM nephropathy AL Amyloidosis Waldenström macroglobulinemia *Illustrative list of autoimmune diseases where B cells may play a role in initiating or maintaining disease, and where NXC-201 may provide a potential treatment Source: Medic Tests. Lee, J. et al. Antigen-specific B cell depletion for precision therapy of mucosal pemphigus vulgaris. J. Clin. Invest. 2020. Mackensen, A. et al. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nat. Med. 2022. Qin C, et al. Anti-BCMA CAR T-cell therapy CT103A in relapsed or refractory AQP4-IgG seropositive neuromyelitis optica spectrum disorders: phase 1 trial interim results. Signal Transduct Target Ther. 2023. Granit V, et al. Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b/2a study. Lancet Neurol. 2023. Shaker OG, et al. Expression of TNF-a, APRIL and BCMA in Behcet's disease. J Immunol Res. 2014. Shimanovsky A, et al. Autoimmune manifestations in patients with multiple myeloma and monoclonal gammopathy of undetermined significance. BBA Clin. 2016. McGlothlin J, et al. Bortezomib and daratumumab in refractory autoimmune hemolytic anemia. Am J Hematol. 2023. Casadevall N. What is antibody-mediated pure red cell aplasia (PRCA)? [published correction appears in Nephrol Dial Transplant. 2005. Yu TS, et al. Abnormalities of bone marrow B cells and plasma cells in primary immune thrombocytopenia. Blood Adv. 2021. Greenberg SA, et al. Plasma cells in muscle in inclusion body myositis and polymyositis [published correction appears in Neurology. 2006. Wilbrink R, et al. B Cell Involvement in the Pathogenesis of Ankylosing Spondylitis. Int J Mol Sci. 2021. Uzzan M, et al. Ulcerative colitis is characterized by a plasmablast-skewed humoral response associated with disease activity. Nat Med. 2022. Zhang Z, Xu Q, Huang L. B cell depletion therapies in autoimmune diseases: Monoclonal antibodies or chimeric antigen receptor-based therapy?. Front Immunol. 2023 6#7Neurotoxicity Restricts CAR-T Adoption Parkinson's Like Symptoms (can develop after 3 months) Limited Hospital Access (can only be dosed in 5% hospitals in the US) CAR-T Neurotoxicity Long Hospital Stay (average -14 days) Memorial Sloan Kettering Cancer Center ●●● IMMIX S BIOPHARMA AACR American Association for Cancer Research CANCER DISCOVERY "Chimeric antigen receptor (CAR) T-cell therapy is highly effective... but is hindered by neurotoxicity." Patient Deaths (On FDA Appproval Labels) doi: 10.1158/2159-8290.CD-17-1319 7#8NXC-201 designed for high activity against disease-causing AL Amyloidosis plasma cells All BCMA CAR-Ts Are Not Created Equal ● a) Uneven BCMA expression and b) frail patient condition has historically prevented conventional, approved CAR-T use in AL Amyloidosis NXC-201 was designed and tested for human AL Amyloidosis treatment, with preclinical testing revealing that: 1 BCMA is expressed in 18 AL Amyloidosis patients at a low-medium level.. BCMA Expression (MFI) 15 15 AL 2 ...NXC-201 CAR-Ts are activated in presence of the AL Amyloidosis target cells ... IFNY (pg/mL) 2.5 x 104- 2x 10- 1.5 x 104- 1x 104- 5103 0 NT NXC-201 3 completely eliminating AL Amyloidosis aberrant plasma cells from patient bone marrow 10³ 10² 10¹. 10⁰ 0- 10³. 10²- 10¹- 10⁰ 0 0 CD138++CD38++: 16.41% 100 10¹ 10⁰ 10² CD38++CD38++0.02% 10¹ 10³ 10² ●●● IMMİX So BIOPHARMA 10³ NXC-201's uniquely favorable tolerability profile (no neurotoxicity + "Single-day CRS") combined with proven preclinical and clinical efficacy make NXC-201 uniquely suited to treat AL Amyloidosis 8 Note: NXC-201 (formerly NBI0101). Infy TNFa for two patients, AL1, AL2. Far right top right quartile selected diseased AL Amyloidosis plasma cell elimination. Far right graph after 33 days co-incubated with NXC-201. Source: Kfir-Erenfeld S, et al. Feasibility of a Novel Academic BCMA-CART (HBI0101) for the Treatment of Relapsed and Refractory AL Amyloidosis. Clin Cancer Res. 2022; Raje N, et al. Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma. N Engl J Med. 2019.;#9N-GENIUS Platform: EXPAND Technology + COBRA Binder (1/2) All BCMA CAR-Ts Are Not Created Equal FIM 3 Key Elements Purpose-Built Cell Therapy Evidence Capture Engine + Relational Database Relating ImmixBio internal data to external to accelerate therapy design, manufacture, and preclinical Proprietary EXPAND technology Applied to multiple cell therapy indications, already utilized to create NXC-201, to potentially increase efficacy and tolerability Atomized, Novel Binding Scaffold Generation Engine Allows us to make the correct binding for every molecule Source: Aherie, N., et al Haematologica. 2022 N-GENIUS PLATFORM CD3Z CD3Zy 4-1BB 4-1BB Produced NXC-201 CD8 Transmembrane Protein Abecma (reference) CD8 Transmembrane Protein CD8 Hinge NXC-201 EXPAND Technology + COBRA Binder CD8 Hinge Tumor Binding Domain ●●● IMMİX S BIOPHARMA COBRA Binder CD8 Signaling Protein CD8 Signaling Protein EXPAND Technology + COBRA Binder Modifications 9#10N-GENIUS Platform: EXPAND Technology + COBRA Binder (2/2) All BCMA CAR-Ts Are Not Created Equal CD3Zy 4-1BB Overview Of Custom EXPAND Technology + COBRA Binder in NXC-201 CD8 Transmembrane Protein 1 Proprietary Optimized CD3Z- 2 "CD3Zy" N-GENIUS PLATFORM NXC-201 EXPAND Technology + COBRA Binder CD8 Hinge Source:. Aherie, N., et al Haematologica. 2022; LaFleur, D. PEGS Boston. 2021 Tumor Binding Domain Proprietary Optimized CD8 Hinge Flexibility Delivers "Digital" Intracellular Signaling Eliminates Neurotoxicity, Reduce CRS Duration Enhances Efficacy In Heavily Pretreated Patients CD8 Signaling Protein "Single amino acid substitutions at key sites can affect CAR-T function over 200-fold range" 3 ●●● IMMİX S BIOPHARMA EXPAND Technology + COBRA Binder Modifications Proprietary Optimized COBRA Binder Enhances Tumor Binding + Ensures High Expression 10#11● ● ● 1 CD32 Proprietary Optimized CD33+ CD8 Delivers "Digital” Intracellular Signaling, Eliminates Neurotoxicity, Reduces CRS Duration CARS rely on activation of CAR-T cells through CD32 derived immunoreceptor tyrosine-based activation motifs (ITAMs), typically 3 ITAM motifs per CAR NXC-201 adds a positively charged amino acid (lysine) next to a tyrosine phosphorylation site, therefore: Impeding phosphorylation of ITAM1 (by affecting protein folding dynamics which block the tyrosine site), thus reducing intracellular reactivity Adding an additional site for ubiquitination, allowing the CAR to be marked for degradation more rapidly than a traditional CAR The combined effect of these modifications is to drive a "digital" signaling of extracellular activity, that is on when antigen is present and off when not Modification of ITAMs is a common theme in third-generation CAR design, with publications in Nature Medicine and by Memorial Sloan Kettering on the topic Source:: Feucht J, et al. Nat Med. 2019; Shah K, et al. Signal Transduct Target Ther. 2021 CD3 14-1BB 4-1BB ITAM domain nature Signal Transduction and Targeted Therapy ←||| 華 • ●●● IMMİX S BIOPHARMA "In activated T cells, the CD32 chain gets ubiquitinated by CBLB at its multiple lysine residues and induces degradation of surface TCRs" doi: 10.1038/s41392-021-00823-w Memorial Sloan Kettering Cancer Center medicine "We hypothesized that the redundancy of CD28 and CD32 signaling in a chimeric antigen receptor (CAR) design incorporating all three CD32 immunoreceptor tyrosine-based activation motifs (ITAMs)11,13 may foster counterproductive T cell differentiation and exhaustion. Therefore, we calibrated ITAM activity by mutating tyrosine residues to impede their phosphorylation and downstream signaling" doi: 10.1038/s41591-018-0290-5 11#12Preclinical Clinical 2 CD8 Hinge NXC-201: Optimized (Decreased) CD8 Hinge Flexibility Resulted In: I >90% reduction in cytokine Irelease in preclinical studies improved human efficacy zero neurotoxicity Efficacy Proprietary Optimized CD33+ CD8 Delivers "Digital” Intracellular Signaling, Eliminates Neurotoxicity, Reduces CRS Duration CRS Neurotoxicity ORR (%) CR (%) CRS, any grade (%) CRS, Grd3+ (%) Duration, CRS (days) 216,058>(90%) Abecma 72 28 85 9 18,016 IFNY (pg/mL): K562-BCMA co-culture bb2121 (Abecma) NXC-201 Interferon-c (IFN-c) release after 24 h of co-culture of CAR T cells with BCMA+ (K562-BCMA, RPMI-8226, U266-B1, H929) targets. 28 NXC-201 87 57 94 14 1 AM.............….....….. Neurotoxicity, Grd1-5 (%). Literature: Optimized (Decreased) I CD8 Hinge Flexibility Resulted In: I ✓ >60% reduction in cytokine release in preclinical studies ✔ improved human efficacy I✓ zero neurotoxicity ●●● S Kymriah 52 40 58 22 7 21 4,0501>(60%) ->(60%) L 11,628 IMMIX BIOPHARMA IFNY (pg/mL): K562-CD19 co-culture Kymriah CD19-BBz(86) CAR+ T cells were stimulated with K562 cells expressing human CD19. Supernatant was harvested after 24 hours of incubation, and the indicated cytokines were measured by cytokine bead array. Results are representative of two-to-four independent experiments. CD19-BBz(86) 73 55 28 0 n/a Optimized (Decreased) CD8 Hinge Flexibility Results in Zero Neurotoxicity, Improved Human Efficacy, and reduction in CRS duration Source:: Ying Z, et al. Nat Med. 2019; Schuster SJ, et al. N Engl J Med. 2019; Assayag, M., et al EBMT 2023; Abecma FDA label; Harush O, et al. Haematologica. 2022; Friedman KM, et al. Hum Gene Ther. 2018. Kymriah: Preclinical is an average of CD8+ and CD4+ T-cells, source: Milone MC, et. Al. Mol Ther.12 2009 Aug;17(8):1453-64. doi: 10.1038/mt.2009.83. Epub 2009 Apr 21. Erratum in: Mol Ther. 2015 Jul;23(7):1278. PMID: 19384291; PMCID: PMC2805264.#133 Optimal Tumor Binding While Ensuring High Expression COBRA Binder COBRA Binder Leads with Heavy Chain Proven Linker of Heavy and Light Chain Employed .. IHSL VH (GGGGS)5 LSH VL (GGGGS) 5 Biomarker Research VL |-- VH 3.6 Source:: Moreno-Cortes E,. et al Front Oncol. 2023; Mazinani M, et al. Biomark Res. 2022. 1.6 Day 10 CAR-T Expansion (10^7) HSL LSH 80 76 Specific Cytotoxicity (%): JeKo1 (ROR1+) co-culture HSL LSH doi: 10.3389/fonc.2023.1200914 "Glycine (Gly) and serine (Ser) residues provide the flexibility necessary for antigen-binding sites to change conformation and maintain good stability in aqueous solutions... prevent[ing] formation of secondary structures and reduc[ing] likelihood of the linker interfering with the folding and function of the scFv" September 19, 2022 doi: 10.1186/s40364-022-00417-w ● ●●● IMMIX S BIOPHARMA NXC-201 COBRA Binder: Heavy Chain - Proven Linker - Light Chain Configuration, enabling: Rapid, Sustained CAR- T Expansion ✓ Improved Cytotoxicity in the presence of antigen 13#14ImmixBio Resolves Neurotoxicity No Parkinson's Like Symptoms Broad Hospital Access (can access vast majority of hospitals in the US) Resolving CAR-T Neurotoxicity Short Hospital Stay (average-3 days) No Deaths Across 58 Patients in Clinical Trial ●●● IMMIX S BIOPHARMA 14#15NXC-201: "Single-Day CRS”, Overcoming Neurotoxicity All BCMA CAR-Ts Are Not Created Equal Neurotoxicity (%) Median CRS Onset (Days) Median CRS Duration (Days) Range CRS Duration (Days) Number of patients (n) NXC-201 I I I 4% 1 1-7 50 NXC-201 Low neurotoxicity vs. -20-30% for others ARCELLX CART-ddBCMA 23% 2 5-8 3-13 31 Johnson Johnson CARVYKTI (ciltacabtagene autoleuce) 23% 7 1-40 97 ll Bristol Myers Squibb Abecma (idecabtagene vicleuce) 28% 1 7 1-63 127 ●●● S IMMIX BIOPHARMA Source: Carvykti and Abecma FDA labels, Arcellx Corporate Presentation. Assayag, N., et al. European Society for Blood and Marrow Transplantation 49th Annual Meeting. Lebel E, et al. Efficacy and Safety of a Locally Produced Novel Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) (HBIO101) for the Treatment of Relapsed and Refractory Multiple Myeloma, International Myeloma Society 20th Annual Meeting, 2023.. Differences exist between trial designs and subject characteristics, and caution should be exercised when comparing data across studies. Figures reflect cross-trial comparison and not results from a head-to head study. 15#16N-GENIUS Technology Platform - Proprietary EXPAND technology and COBRA Binding Domain Are Differentiated Innovations Abecma 4-11 CD32 Carvykti 4-1BB CD3( Note: Graphic representation. COBRA = Codon Optimized Binder for Receptor Antigens - Proprietary Binding Domain CART- ddBCMA 4-1BB CD3( NXC-201 with COBRA Binding Domain 4-1BBY CD3CY N-GENIUS EXPAND Technology ●●● IMMIX do BIOPHARMA 16#17NXC-201 MoA: Next Generation BCMA-targeted CAR-T BCMA EXPRESSING CANCER CELL NXC-201 CAR-T CELL ● NXC-201: FIRST BCMA CAR-T GENERATED BY THE N-GENIUS PLATFORM NXC-201 BCMA Surface Expression NXC-201 BCMA Chimeric Antigen Receptor (CAR) NXC-201 is a next-generation chimeric antigen receptor (CAR) T-cell (CAR-T) produced by our N-GENIUS platform targeting B-cell maturation antigen (BCMA) High Overall Response Rates in AL Amyloidosis and Multiple Myeloma First Outpatient CAR-T: Short CRS duration (median 1 days) starting on day 1 THPT LID NXC-201 - Key Characteristics High Transduction Efficiency (Ensuring efficient manufacturing) *Carvykti data presented at ASH 2019; Abecma data presented at ASH 2017. CART-ddBCMA source Arcellx. Analysis based on cross-trial comparisons of publicly available data reported in ASH 2017 and 2019 and not a head-to-head clinical trial Low Tonic Signaling (Lower off-target toxicity may lead to lower toxicity) NXC-201 was co-cultured with the indicated target T cells and TNFx (B) and IL-2 (C) concentrations secreted in the culture supernatant were determined by ELISA. Anti-Exhaustion Capability (Increased Persistence may lead to efficacy over an extended period of time) NXC-201 was co-cultured overnight then analyzed by flow cytometry for the expression of 4-1BB % CAR+ TNFa (pg/mL) 100% 80% 150 60% 40% 20% 0% 6,000 5,000 4,000 3,000 2,000 1,000 0 Caryvkti No target 4.5±1.8 10 10⁰ 10² 10³ 104 No Target ●●● S BIOPHARMA IMMIX Abecma CART-ddBCMA 100 Source: Development and manufacturing of novel locally produced anti-BCMA CART cells for the treatment of relapsed/refractory multiple myeloma: phase I clinical results. Haematologica. 2022 Oct 6. doi: 10.3324/haematol.2022.281628. Epub ahead of print. PMID: 36200421. 101 T NXC-201 K562-BCMA 57.7 ±3.2 103 K562-BCMA 104 17#18N-GENIUS Technology Platform - NXC-201 rapidly eliminates diseased AL Amyloidosis plasma cells and exits within 30 days (2/2) HB10101 cell/m L Blood HB10101/mL Blood 30 days 2×105. 1.5x105- 1x105- 5x104- 1 0 dFLC (mg/L) 0 20 40 60 Days to CART infusion 80 600 400 · 200 0 dFLC (mg/L) ●●● IMMIX S BIOPHARMA *dFLC (=involved FLC-uninvolved FLC) Source: NXC-201 (formerly known as HBI0101). ImmixBio ASGCT Presentation Los Angeles 2023. E. Lebel et al. Feasibility of a Novel Academic Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) (HBI0101) for the Treatment of Relapsed and Refractory AL Amyloidosis, International Myeloma Society 20th Annual Meeting. 2023. 18#19Nature of AL Amyloidosis Diseased AL Amyloidosis Plasma Cells Express BCMA Target On Cell Surface AL Amyloidosis Is Caused By Malignant Plasma Calls That Produce Misfolded Amyloid Protein ... Bone marrow 1) PLASMA CELL/ MATURE B CELL CLONE Circulation 2) NATIVE LIGHT CHAINS Misfolding/ oligomerization 3) AMYLOID FIBRILS 4) CELL DAMAGE Target tissues/endothelium Which Damages Primary Organs Including: Heart, Liver, Kidney Heart • Heart failure with preserved ejection fraction • Thickened ventricular walls and low voltages on electrocardiography • Dysponea at rest or exertion, fatigue • Hypotension or syncope • Peripheral oedema Source: Merlini, G., et al. Nat Rev Dis Primers. Oct 2018, Front. Cardiovasc. Med., Dec 2022, Hemato 2022, 3(1), 47-62; https://doi.org/10.3390/hemato3010005 ●●● IMMIX S BIOPHARMA Liver • Increased alkaline phosphatase • Hepatomegaly Kidney • Nephrotic range proteinuria • Renal failure • Peripheral oedema 19#20Sizable U.S. Relapsed/Refractory AL Amyloidosis Patient Population Estimated relapsed/refractory US Prevalence ~29,712 in 2023 (Previously Treated) Newly diagnosed AL Amyloidosis US Incidence ~4,000 Relapsed/Refractory -3,040 NXC-201 Eligible US Patients -32,752 ●●● S IMMIX BIOPHARMA Dara-CyBorD: Daratumumab, Bortezomib + cyclophosphamide + dexamethasone. BMD: bortezomib, melphalan, and dexamethasone. Source: Dima D, et al. Diagnostic and Treatment Strategies for AL Amyloidosis in an Era of Therapeutic Innovation. JCO Oncol Pract. 2023; Jimenez- Zepeda VH, et al. Understanding real-world treatment patterns and clinical outcomes in AL amyloidosis patients diagnosed in Canada: A population-based cohort study. EJHaem. 2022; Bou Zerdan M, et al. Systemic AL amyloidosis: current approach and future direction. Oncotarget. 2023; Kumar S, et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol. 2012; Browning S, et al. Hematologic relapse in AL amyloidosis after high-dose melphalan and stem cell transplantation20 Blood. 2017; Palladini G, et al. Presentation and outcome with second-line treatment in AL amyloidosis previously sensitive to nontransplant therapies. Blood. 2018; Staron A, et al. Marked progress in AL amyloidosis survival: a 40-year longitudinal natural history study. Blood Cancer J. 2021;11(8):139; Lu R, Richards TA. AL Amyloidosis: Unfolding a Complex Disease. J Adv Pract Oncol. 2019;10(8):813-825.#21NXC-201 Addresses Sizable U.S. Relapsed/Refractory AL Amyloidosis Patient Population Newly Diagnosed Newly diagnosed US Incidence -4,000 Johnson & Johnson DARZALEX (daratumumab) S 00 mm 400 mg/20 m Darzalex Combination (combined with cyclophosphamide, bortezomib, and/or dexamethasone) Weekly treatments prothena NASDAQ:PRTA Birtamimab (combined with Darzalex, cyclophosphamide, bortezomib, and/or dexamethasone) AstraZeneca CAELUM BIOSCIENCES CAEL-101 Mayo Stage IIIb only Weekly treatments (combined with Darzalex, cyclophosphamide, bortezomib, and/or dexamethasone) Relapsed/Refractory -3,040 Relapsed/Refractory Estimated relapsed/refractory US Prevalence -29,712 in 2023 (Previously Treated) Eligible R/R ALA Patients ~32,752 NXC-201-100% ORR One-time treatment | Monotherapy | All Relapsed/Refractory ALA Patients 32,752 Eligible U.S. AL Amyloidosis Patients No FDA Approved Drugs in Relapsed/Refractory AL Amyloidosis ●●● S IMMİX BIOPHARMA Note: Public information development plans as of 2023. Dara-CyBorD: Daratumumab, Bortezomib + cyclophosphamide + dexamethasone. BMD: bortezomib, melphalan, and dexamethasone. Source: Dima D, et al. Diagnostic and Treatment Strategies for AL Amyloidosis in an Era of Therapeutic Innovation. JCO Oncol Pract, 2023; Jimenez-Zepeda VH, et al. Understanding real-world treatment patterns and clinical outcomes in AL amyloidosis patients diagnosed in Canada: A population-based cohort study. EJHaem. 2022; Bou Zerdan M, et al. Systemic AL amyloidosis: current approach and future direction. Oncotarget. 2023; Kumar S, et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol. 2012; Browning S, et al. Hematologic relapse 21 AL amyloidosis after high-dose melphalan and stem cell transplantation. Blood. 2017; Palladini G, et al. Presentation and outcome with second-line treatment in AL amyloidosis previously sensitive to nontransplant therapies. Blood. 2018; Staron A, et al. Marked progress in AL amyloidosis survival: a 40-year longitudinal natural history study. Blood Cancer J. 2021;11(8):139; Lu R, Richards TA. AL Amyloidosis: Unfolding a Complex Disease. J Adv Pract Oncol. 2019;10(8):813-825.#22NXC-201 - First CAR-T in AL Amyloidosis, a $6 billion market by 2025 Johnson & Johnson DARZALEX (daratumumab) 22% in a sus fue 00 mm 400 mg/20 m 55% Investigator's Choice NM response rates in relapsed/refractory AL Amyloidosis NXC-201 Best Hematologic Response and I Cardiac Response NM AstraZeneca CAELUM BIOSCIENCES CAEL-101 100% Hematologic Overall Response Rate prothena Birtamimab - 39% NXC-201 35% 1 63% 1 Median Reduction from baseline NT-proBNP ● ●●● IMMIX S BIOPHARMA NXC-201 Only CAR-T in AL Amyloidosis NXC-201 100% Overall Response Rate in relapsed/refractory AL amyloidosis (median 6 lines of therapy prior to NXC-201 - all including Darzalex) Cardiac Response exceeds purpose-designed CAEL-101 and Birtamimab for relapsed/ refractory patients Zero Neurotoxicity of any grade in AL Amyloidosis Birtamimab Source: Gertz MA et al. J Clin Oncol. 2016; CAEL-101 source: Edwards CV, et al. Blood. 2021 Darzalex source: Theodorakakou, et al, 2022 - Outcomes of Patients with AL Amyloidosis after Failure of Daratumumab-Based Therapy - Blood (2022) 140 (Supplement 1): 4275-4276 https://doi.org/10.1182/blood-2022-165403., Point-of-care CART manufacture and delivery: Expanding access to CART therapy via local institutions, Hadassah Medical Center experience. Poster Presentation, European Society for Blood and Marrow Transplantation and European Hematology Association 5th European CAR T-cell Meeting. 2023 Feb 9-11. Assayag, M, et al. Stepensky. Point-of-care CART manufacture and delivery for the treatment of multiple myeloma and AL amyloidosis: the experience of Hadassah Medical Center. Poster Presentation, European Society for Blood and Marrow Transplantation 49th Annual Meeting, 2023 Apr 23-26. Asherie N. et al, Oral Presentation. ASGCT, 2023.The Amyloidosis market was $3.6 billion in 2017, expected to reach $6 billion in 2025, according to Grand View Research. Differences exist between trial designs and subject characteristics, and caution should be exercised when comparing data across studies.. Figures reflect cross-trial comparison and not results from a head-to head study. Differences exist between trial designs and subject characteristics, and caution should be exercised when comparing data across studies. Lebel, E., et al. Feasibility of a Novel Academic Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) (HBI0101) for the Treatment of Relapsed and Refractory AL Amyloidosis. American Society of Hematology 65th Annual Meeting, 2023. 22#23N-GENIUS Technology Platform - NXC-201: First "Single-Day CRS" CAR-T - Narrow, Predictable Side Effect Window in Multiple Myeloma NXC-201 Johnson & Johnson CARVYKTI Iciltacabtagene autoleucell Median onset range of duration of CRS Median onset range of duration of ICANS neurotoxicity Side-Effect Window Baseline SBCMA -460,000 pg/mL Bristol Myers Squibb Median onset range of duration of CRS Median onset range of duration of ICANS neurotoxicity Side-Effect Window Abecma (idecabtagene vicleuce) Baseline SBCMA -500,000 pg/mL Baseline SBCMA -203,000 pg/mL Median onset range of duration of CRS Median onset range of duration of ICANS neurotoxicity 1 Side-Effect Window 1-7 CRS duration Zero neurotoxicity sBCMA AUC 田田 sBCMA AUC CAR-T cells CAR-T cells 30 days -40 CAR-T cells SBCMA area under the curve (AUC) CRS duration 1-63 CRS duration CAR-T cell expansion in the blood -Relative sBCMA tumor marker level in blood --Limit of Quantitation, sBCMA ICANS Neurotoxicity duration 2-297 60 days 田田田田田田 ICANS Neurotoxicity duration 1-578 田田田田田田田田田田田 NXC-201 Produces Deepening Response Transformations Day 200-240 After Treatment (median 5.7 months of follow-up as of Feb 9 2023 data cutoff) Pt. 23 Day 240 VGPR CR 10-5 Pt. 11 Day 225 VGPR MRD+ → VGPR MRD- Pt. 22 Day 200 VGPR → CR 10-5 155 days ... do 田田田田田田田 IMMIX BIOPHARMA 1 NXC-201: Max 7-day CRS Others: up to 63 day CRS 2 NXC-201: Low (4%) Neurotoxicity Others: Up to 578-day neurotoxicity 3 NXC-201: SBCMA reduced in -30 days Others: SBCMA reduced in -60-155 days 4 NXC-201: CAR-T cells exit body after sBCMA reduced Others: CAR-T cells remain elevated, causing 田田 ← Days since CAR-T cell infusion → *NXC-201: No measurements available beyond 30 days in multiple myeloma as of the Feb 2023 data cutoff (in human data from AL Amyloidosis, NXC-201 clears system in < 30days as seen on the next slide) 23 Source: FDA labels; company presentations; EMA assessment report; Asherie, N., et al. Haematologica, 2022. Frigault, M., et al. Blood Advances, 2022; Shen, Y, et al. Curr Res Transl Med. 2023; Janssen Science; Figures reflect cross-trial comparison and not results from a head-to head study. Differences exist between trial designs and subject characteristics, and caution should be exercised when comparing data across studies; Y-axes units (log10) for T-cell expansion: cells/mL blood (NXC-201) and vector transgene copies/ug of genomic DNA (Carvykti, Abecma), for relative SBCMA: 0-200 (NXC-201), ng/mL (Abecma) and pg/mL (Carvykti); Lebel E, et al. Efficacy and Safety of a Locally Produced Novel Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) (HBI0101) for the Treatment of Relapsed and Refractory Multiple Myeloma, International Myeloma Society 20th Annual Meeting. 2023. prolonged neurotoxicity and CRS#24Only CAR-T in BCMA-exposed multiple myeloma, a rapidly growing patient segment (1/2) Representative Treatment Results Representative patient number growth Newly diagnosed Bortezomib, lenalidomide, and (VRD) is stand dex therapy for newly diagnosed multiple myeloma -50% relapse at month 30 Standard-of-care refractory BCMA-targeted antibodies (Tecvayli-J&J; Elrexfio-Pfizer) bispecifics -50% relapse at month 11-15 ●●● IMMIX S BIOPHARMA BCMA-exposed, a rapidly growing patient segment Limited treatment options (no approved treatments) NXC-201: 75% overall response rate; 50% complete response rate "Recent studies of anti-BCMA BsAbs, ... demonstrate that patients may experience disease progression after treatment, leaving them with few other treatment options." Cohen et al, Blood, 2023 Source: https://doi.org/10.1038/s41591-023-02528-9 Nature Medicine, Lancet Oncol. 2020 October; 21(10): 1317-1330. doi:10.1016/S1470-2045(20)30452-6, ; Teclistamab in Relapsed or Refractory Multiple Myeloma New England Journal of Medicine Aug 11 2022. Figures reflect cross-trial comparison and not results from a head-to head study. Differences exist between trial designs and subject characteristics, and caution should be exercised when comparing data across studies. Cohen et al 2023 https://doi.org/10.1182/blood.2022015526 24#25Only CAR-T in BCMA-exposed multiple myeloma, a rapidly growing patient segment (2/2) Complete Response Rates in BCMA-exposed multiple myeloma NXC-201 50% NXC-201 67% improvement in response rates Johnson-Johnson Bristol Myers Pfizer Squibb CARVYKTI™ Iciltacablagene autoleuce 2022 I 30% Abecma (decabragene vicleuce) 2021 FDA approval year 29% ELREXFIO (elranatamab-bcmm) 2023 34% ●●● IMMIX S BIOPHARMA Source: 49th EBMT (NXC-201) presentation, Elrexfio FDA approval label, Cohen et al 2023 https://doi.org/10.1182/blood.2022015526 Blood 2022 https://doi.org/10.1182/blood-2022-164884. Note: Elrexfio reflects overall response rate (complete response rate not reported on FDA label). Figures reflect cross-trial comparison and not results from a head-to head study. Differences exist between trial designs and subject characteristics, and caution should be exercised when comparing data across studies. 25#26NXC-201 Clinical Development Plan Through FDA BLA Submissions Expansion Into Additional Sites in the U.S. Planned for Q4 2023/01 2024 Target Indication Relapsed/refractory AL Amyloidosis NXC-201 Select Autoimmune Indications NXC-201 BCMA-exposed multiple myeloma NXC-201 Phase 1b/2a NXC-201 Ongoing: NEXICART-1 (NCT04720313) U.S. IND Approved Phase 1b/2a NXC-201 Ongoing: NEXICART-1 (NCT04720313) Phase 2a Open Label, Potentially Pivotal Trial Trial Proof-of-concept clinical data to be generated in 2nd line therapy Relapsed/refractory Light Chain (AL) Amyloidosis >30 Patients Single arm, open label Select Autoimmune Indications Single arm, open label Recommended Phase 2 Dose (RP2D) Already Relapsed/refractory Multiple Myeloma Established at 800 million NXC-201 CAR+T Cells 97 patients At RP2D Single arm, open label Submit to FDA (BLA) Submit to FDA (BLA) Clinical Effectiveness Submit to FDA (BLA) ●●● IMMIX S BIOPHARMA Status -25% Patients Dosed Site Activation -50% Patients Dosed FDA approval precedents include: Abecma/BMS (single arm study 100 patients in efficacy results population, FDA approved 2021); Carvykti/J&J (single arm study 97 patients in efficacy results population, FDA approved 2022); Elrexfio/Pfizer (single arm study 97 patients in efficacy results population, FDA approved 2023) 26#27NXC-201 "Single-Day CRS" Potentially Increases CAR-T Addressable Market to -3,000 U.S. Centers (From -200 today) 2 2 Now: 198 centers 2 CAR-T center 2 2 2 Source: American Hospital Directory; BMT Infonet; Wikipedia Commons 2 요 요 2 요 9 9.0 a 14:0 9 9 10 80 18 B 29 9 of 9 9 110 요 9 9 S 요 2 Future: 3,092 centers 9 9 9 요 9 9 9 Potential CAR-T Center g 9 9 99 9 요 9 9 9 90 ●●● IMMIX S BIOPHARMA 27#28IMX-110 Clinical Results Demonstrate Potential for Best-in-Class Efficacy & Safety in Soft Tissue Sarcoma (STS), and Encouraging Efficacy in Colorectal Cancer 100% Relapsed/Refractory Soft Tissue 68% Sarcoma 4.2 2.7 2.6 ht. 62% 58% Disease Control at 2 months IMX-110 7L Johnson-Johnson Yondelis (trabectedin 2L 4.0 median PFS (months) Doxorubicin 1L 3L Eisai Relapsed/Refractory Metastatic pMMR Colorectal Cancer Halaven d 75% NR (1% ORR reported) 2.0 2.0 Tumor Shrinkage median PFS (months) IMX-110 + PD-19L B BAYER K Stivarga fragorafenibles 4L ● ● ● ●●● IMMIX S BIOPHARMA IMX-110 category leading progression free survival (PFS) in heavily pretreated patients with zero drug-related SAES IMX-110 100% Disease Control at 2 months (Doxorubicin 68% Yondelis 62% Halaven 58%) IMX-110 treated STS patients had 3-13 median prior lines of therapies IMX-110 + PD-1 treated r/r colorectal cancer showed 75% tumor shrinkage and mPFS not reached (NR) at 2 months in patients had 8 median prior lines of therapies Note: mPFS is Median Progression Free Survival. Dollar amounts are annual drug sales. Adapted from: Lorigan et al. Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol. 2007 Jul 20;25(21):3144-50. doi: 10.1200/JCO.2006.09.7717. Judson et al. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. Lancet Oncol. 2014 Apr;15(4):415-23. doi: 10.1016/S1470-2045(14)70063-4. Chawla et al. First-Line Aldoxorubicin vs Doxorubicin in Metastatic or Locally Advanced Unresectable Soft-Tissue Sarcoma: A Phase 2b Randomized Clinical Trial. JAMA Oncol. 2015 Dec;1(9):1272-80. doi: 10.1001/jamaoncol.2015.3101. Tawbi et al. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol. 2017 Nov;18(11):1493-1501. doi: 10.1016/S1470-2045(17)30624-1. D'Angelo et al. Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials. Lancet Oncol 2018 Mar;19(3):416-426. doi: 10.1016/S1470- 2045(18)30006-8. Schöffski et al. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. Lancet. 2016 Apr 16;387(10028):1629-37. doi: 10.1016/S0140-6736(15)01283-0. D'Angelo et al. Pilot study of NKTR214 and nivolumab in patients with sarcomas. Journal of Clinical Oncology 2019 37:15_suppl, 11010-11010. DOI: 10.1200/JCO.2019.37.15_suppl.11010. van der Graaf et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2012 May 19;379(9829):1879-86. doi: 10.1016/S0140-6736(12)60651-5. Epub 2012 May 16. Figures reflect cross-trial comparison and not results from a head-to head study. Differences exist between trial designs and subject characteristics, and caution should be exercised when comparing data across studies. The global soft tissue sarcoma market is estimated to reach USD 6,465.7 million by 2030 from USD 2,943.3 million in 2019 according to MedGadget. Per Stirvarga FDA approval label, Stivarga 1% Overall Response Rate (ORR) reported, tumor shrinkage not reported. pMMR: proficient mismatch repair 28#29Upcoming Catalysts I NXC-201 ✓ 2023 - Ongoing Phase 1b/2 results with NXC-201 Data pending release: relapsed/refractory Multiple Myeloma - 63 patients treated ✓ Data pending release: relapsed/refractory AL amyloidosis - 10 patients treated ✓ Data pending release: More patients (current enrollment pace -5 patients/month) ✓2023 - Pre-IND meeting with FDA ✓2023 - File IND for U.S. Phase 1b/2 trial for NXC-201 I✓ 2023 Q4 - U.S. IND Cleared Already ✓2H25 - Planned Biologics License Applications (BLA) submission for NXC-201 once 100 patients are dosed IMMIX BIOPHARMA ●●● IMMIX S BIOPHARMA IMX-110 ✓ 2023 - Release data on a rolling basis from Phase 1b/2a advanced solid tumor trial with IMX-110 + tislelizumab combination therapy ✓ 2023 - Continue enrolling patients into Phase 1b/2a trial evaluating IMX-110 in STS ✓ 2023 - Ongoing preclinical studies with IMX-110 ✓ 2023 - Add Phase 2a clinical sites for IMX-110 ✓ 2024 - Report Phase interim 2a results for IMX-110 I in STS Other Candidates ✓ 2H23 - Finish preclinical studies with IMX-111 ✓ 2H23 - Finish preclinical studies with IMX-120 29#30ImmixBio Pipeline: Autoimmune CAR-T Company with 73 patients dosed to-date Stage Clinical Preclinical Tx Type CAR-T TSTX CAR-T CAR-T TSTX TSTX Candidate NXC-201 target BCMA iMX-110 TME Normalization™ Technology NXC-301 NXC-401 iMX-111 iMX-120 Indication AL Amyloidosis Autoimmune Multiple Myeloma Solid Tumors, Colorectal, Soft Tissue Sarcoma + Tislelizumab (anti-PD-1) ALL, LBCL, MCL AML Colorectal Cancer Inflammatory Bowel Disease Preclinical Phase 1b/2a Ongoing IND-enabled Phase 1b/2a Ongoing Phase 1b/2a Ongoing Preclinical Phase 1 Preclinical Preclinical Preclinical Phase 2 Phase 3 Approval Collaboration BeiGene Progress 10 patients treated in relapsed/refractory AL Amyloidosis • 100% overall response rate • 70% complete response rate • Indication to be announced 63 patients treated ● 95% overall response rate ● ● ● US FDA Orphan Drug Designation (ODD) for AL Amyloidosis Granted ● ●●● IMMİX S BIOPHARMA US FDA Orphan Drug Designation (ODD) for Multiple Myeloma Granted US FDA Orphan Drug Designation (ODD) for STS Granted US FDA Rare Pediatric Disease Designation (RPDD) Granted Zero drug-related SAES CMC: 7 GMP batches manufactured to-date In preclinical development EXPAND technology In preclinical development • EXPAND technology Tissue Specific Biologic™ Targeted biomarker GLUT1 overexpressed in stage 3/4 colorectal cancer and additional tumor types Tissue Specific Biologic™ 12-month end-to-end clinical trial leading to potential approval in multi billion-dollar indication Global Rights • 600 * IMMIX fo BIOPHARMA 00 • ** *** do IMMIX BIOPHARMA ** ... +4 do IMMIX BIOPHARMA IMMIX BIOPHARMA IMMIX BIOPHARMA IMMIX BIOPHARMA IMMIX BIOPHARMA BIOPHARMA Note: 95% overall response rate in multiple myeloma isf or patients without prior BCMA targeted therapies. Treatment. Source: Lebel E, et al. Efficacy and Safety of a Locally Produced Novel Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) (HB10101) for the Treatment of Relapsed and Refractory Multiple Myeloma, International Myeloma Society 20th Annual Meeting. 2023. Lebel, E., et al. Feasibility of a Novel Academic Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) (HBI0101) for the Treatment of Relapsed and Refractory AL Amyloidosis. American Society of Hematology 65th Annual Meeting. 2023. Differences exist between trial designs and subject characteristics, and caution should be exercised when comparing data across studies. 30#31NXC-201 Entering Large Markets At a Pivotal Moment Hematologic cancers market opportunity is $60bn today growing to $120bn in 2028. ● Market Size Multiple Myeloma ("MM") is 3rd most common blood cancer, impacting 176,404 patients annually, with life expectancy of 5 years. AL Amyloidosis is developed by 14,982 people annually-with no available treatments as standard of care other than bone marrow transplant (only 20% patients eligible) Hematologic Cancers Market Size $120B... Darzalex/ Carvykti/ Daratumumab Cilta-cel Johnson & Johnson Johnson & Johnsen $60B... Abecma/ Ide-cel Bristol Myers Squibb Venclexta/ Venetoclax abbvie Ninlaro/ Kyprolis/ Ixazomib Carfilzomib Takeda Birtamimab AMGEN prothena 1 2 3 "Patients With Multiple Myeloma May Face CAR T-Cell Shortages" The ASCO Post Sep 25, 2022 4 Best ORR CR/SCR Why Now Leveraging market CAR-T experience so far-manufacturing consistency, automation technology, efficacy, safety. Demand for MM CAR-Ts continues to exceed supply - only 2 MM CAR-Ts on the market: Ill Bristol Myers Squibb Abecma decobtogene vicleucell . NXC-201 800 x 106 CAR+T cells 95% "Gilead lands new cell therapy for Kite in $225M Arcellx deal, providing global scale for future J&J-Legend showdown" Dec 9, 2022 Bispecifics/Allogeneic CAR-Ts still work in progress. 1 61% Still common with approved CAR-Ts: High grade Cytokine Release Syndrome grade 3) and neurotoxicity side-effects. ●●● IMMIX S BIOPHARMA CARVYKTI (ciltacabtagene autoleucell Allogeneic BCMA-CAR-T 71% 25% FIERCE Biotech BCMA bispecific engagers 75% 43% Sources: Multiple Myeloma life expectancy source - Arcellx July 2022 investor presentation (NADSAQ:ACLX). Multiple myeloma annual incidence source: GLOBOCAN 2020. Hematologic cancers market size source: reportsanddata.com. AL Amyloidosis annual incidence source: Global epidemiology of amyloid light-chain amyloidosis https://doi.org/10.1186/s13023-022-02414-6. AL Amyloydosis transplant eligibility source: Bone Marrow Transplant. 2013 Oct;48(10):1302-7. doi: 10.1038/bmt.2013.53; Lebel E, et al. Efficacy and Safety of a Locally Produced Novel Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) (HBI0101) for the Treatment of Relapsed and Refractory Multiple Myeloma, International Myeloma Society 20th Annual Meeting, 2023. Note: Allo BCMA CAR-T scope includes ALLO-715 (Allogene); CYAD-211 (Celyad), BCMA Bispecific Engagers scope includes Teclistamab (Janssen); Elranatamab (Pfizer); ABBV-383 (AbbVie); REGN5458 (Regeneron); CC-93269 (Bristol Myers); HPN217 (Harpoon) as of March 1 2022. 31#32Potential to Disrupt the $230bn+ Oncology and Immunology Categories 2030 Market Opportunity Broad platforms driving next-generation therapies in blood cancers, solid tumors and immunology MULTIPLE MYELOMA $29B+ CELL THERAPY PD-1 ANNUAL SALES - KEYTRUDAⓇ + OPDIVOⓇ $29B SOLID TUMORS + IMMUNOLOGY AL Amyloidosis $4B+ CELL THERAPY CELL THERAPY Hematologic Malignancies Acute lymphocytic leukemia Large B-Cell Lymphoma Mantle Cell Lymphoma Acute Myeloid Leukemia ●●● IMMIX S BIOPHARMA SOLID TUMORS + IMMUNOLOGY Soft Tissue Sarcoma Colorectal Cancer Inflammatory Bowel Disease $175B+ Sources: Hematologic cancers market size source: reportsanddata.com. Merck Financial Results, 2022 Bristol Meyers Squibb Financial Results. AL Amyloidosis market size according to Grand View Research. Hematological Malignancies reportsanddata.com, ALL allied market research.com, LBCL datamintelligence.com, MCL dataintelio.com, AML GlobalData, STS MedGadget, CRC Industry Arc, Prometheus Biosciences S-1. 32#33NXC-201 Clinical Results Demonstrate Potential for Best-in-Class Efficacy & Safety in AL (light chain) Amyloidosis Patient #s Hematologic Overall Response Rate | Hematologic Complete Response Rate Hematologic CR + VGPR I Cardiac response - (NT-proBNP median reduction) Renal response (%) Median prior lines of therapy % pretreated with CD38-targeted treatment (Darzalex/other) Source Relapsed/Refractory Light chain (AL) Amyloidosis NXC-201 NEXCELLA NEXT GENERATION CELL THERAPIES NXC-201 Monotherapy One-Time Treatment n=10 100% 70% 90% 63% 67% 6 100% 29th ASGCT 2023, 49th EBMT Meeting 2023, 5th European CAR-T Meeting, Clinical Cancer Research 20th IMS Meeting 2023 65th ASH Meeting 2023 Johnson & Johnson DARZALEX (daratumumab) i Darzalex Combination (combined with cyclophosphamide, bortezomib, and/or dexamethasone) Weekly treatments n=9 22% 0% 22% 1 100% Theodorakakou, et al, Blood 2022 Investigator's Choice (Darzalex comination with bortezomib or IMiD, venetoclax, belantamab mafodotin, bortezomb- baaed, lenalidomide-based, ptpomalidomide, ixazomib or alkylating agent) n=31 55% ? 45% Landscape 1 100% Theodorakakou, et al, Blood 2022 AstraZeneca CAELUM BIOSCIENCES CAEL-101 Weekly treatments n=10 (renal) n=24 (cardiac) 39% 20% 2 ? Blood 2021 ●●● S IMMİX BIOPHARMA prothena Birtamimab Birtamimab Combined with SOC CyBorD Weekly treatments N = 14 (cardiac) N = 15 (renal) 35% 60% 2 0% Gertz, et al. JCO 2016 14,982 patient annual incidence Birtamimab Source: Gertz MA et al. First-in-Human Phase I/II Study of NEOD001 in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction. J Clin Oncol. 2016 Apr 1;34(10):1097-103. doi: 10.1200/JCO.2015.63.6530. Epub 2016 Feb 8. PMID: 26858336; PMCID: PMC5470113. (Birtamimab development was paused + restarted). CAEL-101 source: Edwards CV, et al. Phase 1a/b study of monoclonal antibody CAEL-101 (11-1F4) in patients with AL amyloidosis. Blood. 2021 Dec 23;138(25):2632-2641. doi: 10.1182/blood.2020009039. PMID: 34521113; PMCID: PMC8703360.. Darzalex source: Theodorakakou, et al, 2022 - Outcomes of Patients with AL Amyloidosis after Failure of Daratumumab-Based Therapy-Blood (2022) 140 (Supplement 1): 4275-4276 https://doi.org/10.1182/blood-2022-165403, Point-of-care CART manufacture and delivery: Expanding access to CART therapy via local institutions, Hadassah Medical Center experience. Poster Presentation, European Society for Blood and Marrow Transplantation and European Hematology Association 5th European CAR T-cell Meeting. 2023 Feb 9-11. Assayag M, et al. Point-of-care CART manufacture and delivery for the treatment of multiple myeloma and AL amyloidosis: the experience of Hadassah Medical Center. Poster Presentation, European Society for Blood and Marrow Transplantation 49th Annual Meeting. 2023 Apr 23-26. Asherie N. et al, BCMA- Targeted CART (HBI0101), a Safe and Efficacious Novel Modality of Treatment for Light Chain Amyloidosis (AL) Patients. Oral Presentation. ASGCT-American Society of Gene & Cell Therapy 29th Annual Meeting. May 19, 2023. Figures reflect cross-trial comparison and not results from a head-to head study. Lebel E,et al. Feasibility of a Novel Academic Anti-BCMA 33 Chimeric Antigen Receptor T-Cell (CART) (HBI0101) for the Treatment of Relapsed and Refractory AL Amyloidosis, International Myeloma Society 20th Annual Meeting. 2023. Differences exist between trial designs and subject characteristics, and caution should be exercised when comparing data across studies. Lebel, E., et al. Feasibility of a Novel Academic Anti- BCMA Chimeric Antigen Receptor T-Cell (CART) (HBI0101) for the Treatment of Relapsed and Refractory AL Amyloidosis. American Society of Hematology 65th Annual Meeting, 2023.#34NXC-201 Clinical Results Demonstrate Potential for Best-in-Class Efficacy & Safety in Multiple Myeloma Patients Clinical Data No Prior BCMA-Targeted Therapy Patient #s Extramedullary disease (EMD) High risk cytogenetics Overall Response Rate Complete Response Rate ICANS Neurotoxcity (all grades) CRS, grade >= 3 Potential hospital stay length based on available data Source NEXCELLA HEXATION CLL THE planned RP2D 800 million CAR+T cells NXC-201 Monotherapy n=38 24% 62% 95% 61% -3 days 49th EBMT Meeting 2023 20th IMS Meeting 2023 ARCELLX (NASDAQ: ACLX) CART- ddBCMA 100 + 300M cells n=31 39% 100% 71% 23% 3% -14 days 2022 NASDAQ IPO S-1 Johnson Johnson CARVYKTI fittacattajent autoleucell n=97 13% 24% 98% 78% 23% (2 deaths) 5% (1 death) -14 days FDA Approval Label Bristol Myers Squibb Abecma lidecatogene videoe n=144 50% 36% 88% 48% 8.5% -14 days Ferreri et al, Blood 2022 NEXCELLA Yes Prior BCMA-Targeted Therapy planned RP2D 800 million CAR+T cells NXC-201 Monotherapy n=12 24% 62% 75% 50% 0% -3 days 49th EBMT Meeting 2023 Investigator's choice N=275 ? 29% 31% 2% N/A N/A N/A Gandhi, et al 2019 Johnson Johnson CARVYKTI (citacabtagere autoleucel n=20 25% 15% 60% 30% 20% 0% -14 days Blood 2023 - Cohen et al Bristol Myers Squibb Abecma (decabtogene vicleuce) n=49 50% 36% 74% 29% 8.5% 2% -14 days Ferreri et al, Blood 2022 Overall - Mixed (BCMA Pretreated + not) NEXCELLA HET GENERATION CELL THERAP includes all patients (with and without Prior BCMA-Targeted Therapy) treated at 800 million CAR+T cells NXC-201 Monotherapy n=50 24% 62% 90% 58% 4% 14% -3 days ●●● IMMIX S BIOPHARMA 20th IMS Meeting 2023 Ill Bristol Myers Squibb™ Abecma (idecabtagene vicleuce) n=100 36% 37% 72% 28% 28% 9%² (1 death) 14 days FDA Approval Label 176,404 (35,730 US) patient annual incidence ¹All grades of neurotoxicity 2 The safety data described in this section reflect the exposure to ABECMA in the KarMMa study, in which 127 patients with relapsed/refractory multiple myeloma received ABECMA. 3a3bFor of the first 20, 42 patients treated with NXC-201 at all doses, respectively Source: Development and manufacturing of novel locally produced anti-BCMA CART cells for the treatment of relapsed/refractory multiple myeloma: phase I clinical results. Haematologica. 2022 Oct 6. doi: 10.3324/haematol.2022.281628. Epub ahead of print. PMID: 36200421, Feasibility of a Novel Academic BCMA-CART (HBI0101) for the Treatment of Relapsed and Refractory AL Amyloidosis. Clin Cancer Res. 2022 Dec 1;28(23):5156-5166. doi: 10.1158/1078-0432.CCR-22-0637. PMID: 36107221., Point-of-care CART manufacture and delivery: zExpanding access to CART therapy via local institutions, Hadassah Medical Center experience. Poster Presentation, European Society for Blood and Marrow Transplantation and European Hematology Association 5th European CAR T-cell Meeting. 2023 Feb 9- 11. Assayag M, et al. Point-of-care CART manufacture and delivery for the treatment of multiple myeloma and AL amyloidosis: the experience of Hadassah Medical Center. Poster Presentation, European Society for Blood and Marrow Transplantation 49th Annual Meeting. 2023 Apr 23-26. Blood 2022 https://doi.org/10.1182/blood-2022-164884. Cohen et al 2023 34 https://doi.org/10.1182/blood.2022015526. Lebel E, et al. Efficacy and Safety of a Locally Produced Novel Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) (HBI0101) for the Treatment of Relapsed and Refractory Multiple Myeloma, International Myeloma Society 20th Annual Meeting, 2023. Figures reflect cross-trial comparison and not results from a head-to head study. Differences exist between trial designs and subject characteristics, and caution should be exercised when comparing data across studies.#35NXC-201 Clinical Results Demonstrate Potential for Best-in-Class Efficacy & Safety in Multiple Myeloma, a $29 billion market by 2027 71% Complete Response Rate in Relapsed/Refractory Multiple Myeloma 78% 48% No BCMA 61% ARCELLX NASDAQ: ACLX CART-ddBCMA 30% 29% Yes BCMA Johnson & Johnson CARVYKTI Iciltacabtagene autoleucell 50% Bristol Myers Squibb™ 28% Overall NXC-201 58% ● ● ●●● S IMMIX BIOPHARMA NXC-201 Class leading efficacy in multiple myeloma NXC-201: low (4%) neurotoxicity grade 1-2 (9- 23% for others) • -80% reduction in hospitalization cost - 3 day hospital stay for NXC-201 (14 days for others) Abecma lidecabtagene vicleuce) "Yes/No BCMA" refers to prior treatment with BCMA-targeted therapies. "Overall" includes a mix of Yes/No Source: Development and manufacturing of novel locally produced anti-BCMA CART cells for the treatment of relapsed/refractory multiple myeloma: phase I clinical results. Haematologica. 2022 Oct 6. doi: 10.3324/haematol.2022.281628. Epub ahead of print. PMID: 36200421., Feasibility of a Novel Academic BCMA-CART (HBI0101) for the Treatment of Relapsed and Refractory AL Amyloidosis. Clin Cancer Res. 2022 Dec 1;28(23):5156-5166. doi: 10.1158/1078-0432.CCR-22-0637. PMID: 36107221., Point-of-care CART manufacture and delivery: zExpanding access to CART therapy via local institutions, Hadassah Medical Center experience. Poster Presentation, European Society for Blood and Marrow Transplantation and European Hematology Association 5th European CAR T-cell Meeting, 2023 Feb 9-11. Assayag M, et al. Stepensky. Point-of-care CART manufacture and delivery for the treatment of multiple myeloma and AL amyloidosis: the experience of Hadassah Medical Center. Poster Presentation, European Society for Blood and Marrow Transplantation 49th Annual Meeting. 2023 Apr 23-26. Blood 2022 https://doi.org/10.1182/blood-2022-164884. Cohen et al 2023 https://doi.org/10.1182/blood.2022015526. E. Lebel et al. Efficacy and Safety of a Locally Produced Novel Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) (HBI0101) for the Treatment of Relapsed and Refractory Multiple Myeloma, International Myeloma Society 20th Annual Meeting. 2023. Differences exist between trial designs and subject characteristics, and caution should be exercised when comparing data across studies. The $13.9 billion Multiple Myeloma market in 2017 is expected to reach $28.7 billion in 2027 according to Wilcock, et al. Nature Reviews. Figures reflect cross-trial comparison and not results from a head-to head study.. 35#36NXC-201 Clinical Highlights: 100% ORR / 95% ORR in AL / MM, "Single-Day CRS" Relapsed/refractory Light chain (AL) Amyloidosis 100% Overall Response + 70% Complete Response in Relapsed/Refractory Amyloidosis Patients, 1 responder with 23.7+ months DoR 4.1 months median duration of response at a median follow-up of 6.9 months 2-stage improvement in NYHA stage was observed with NXC-201 Median 63% reduction in NT-proBNP from baseline Outpatient CAR-T Potential Published in Clinical Cancer Research 2022 + 5th European CAR-T Cell Meeting + 49th EBMT meeting + 29th ASCGT 2023 (Los Angeles) + 20th IMS 2023 + 65th ASH 2023 Data in 10 patients so far Johnson-Johnson DARZALEX (daratumumab) $8Bn Annual Sales NXC-201 Eligible US Patients -32,752 Relapsed/refractory Multiple Myeloma 95% Overall Response Rate in Heavily Pretreated Multiple Myeloma Patients 61% CR/SCR rate Low (4%) Neurotoxicity observed No Grade 4 Cytokine Release Syndrome (CRS) Observed at planned RP2D 800 million CAR+T cells Outpatient CAR-T Potential Published in Haemotologica 2022 + 5th European CAR-T Cell Meeting + EBMT 49th Annual meeting + 20th IMS Data in 63 patients so far Bristol Myers Squibb Revlimid ilonadonid3 $11Bn Annualized Sales Johnson & Johnson DARZALEX (daratumumab) 1005400DZYL se ●●● IMMİX S BIOPHARMA illi Bristol Myers Squibb Pomalyst foomaloomide) capsules 1.2.3.4 mg $2.5Bn Annualized Sales $8Bn Annual Sales Bristol Myers Squibb Abecma fidecubungene viceucel FDA Approved Anti-BCMA Autologous CAR-T 176,404 patient annual incidence Johnson & Johnson CARVYKTI [ciltacabtagene autoleucel) FDA Approved Anti-BCMA Autologous CAR-T Source: BMS First Quarter 2022 financial results; "Genmab Improves Its 2022 Financial Guidance" November 3 2022, Celgene Second Quarter 2019 Operating and Financial Results., Development and manufacturing of novel locally produced anti-BCMA CART cells for the treatment of relapsed/refractory multiple myeloma: phase I clinical results. Haematologica. 2022 Oct 6. doi: 10.3324/haematol.2022.2816: Epub ahead of print. PMID: 36200421., Feasibility of a Novel Academic BCMA-CART (HB10101) for the Treatment of Relapsed and Refractory AL Amyloidosis. Clin Cancer Res. 2022 Dec 1;28(23):5156-5166. doi: 10.1158/1078-0432.CCR-22-0637. PMID: 36107221., Point-of-care CART manufacture and delivery: Expanding access to CART therapy via local institutions, Hadassah Medical Center experience. Posti Presentation, European Society for Blood and Marrow Transplantation and European Hematology Association 5th European CAR T-cell Meeting. 2023 Feb 9-11. Assayag M, et al. Point-of-care CART manufacture and delivery for the treatment of multiple myeloma and AL amyloidosis: the experience of Hadassah Medical Center. Poster Presentation, European Society for Blood and Marrow Transplantation 49th An Meeting. 2023 Apr 23-26. Lebel E, et al. Efficacy and Safety of a Locally Produced Novel Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) (HB10101) for the Treatment of Relapsed and Refractory Multiple Myeloma, International Myeloma Society 20th Annual Meeting. 2023. Lebel, E., et al. Feasibility of a Novel Academic Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) (HB10101) for the Treatment of Rela and Refractory AL Amyloidosis. American Society of Hematology 65th Annual Meeting, 2023.#37Proportion of NXC-201 Patients with SCR/CR Increased Over Time in Relapsed/Refractory Multiple Myeloma 100% 80% 60% 40% 20% 0% 50% 31% 2% 17% ■ Best response in patients with at least 1 month follow up SD PR VGPR 75% 25% SCR/CR Best response in patients with at least 6 months follow up 83% 17% ●●● IMMIX S BIOPHARMA Best response in patients with at least 9 months follow up The patients included in this analysis are determined by those who have had their 1- (n=42), 6-(n-16), 9- (n=6) month follow-up visits, respectively, per protocol. Source: Point-of-care CART manufacture and delivery: Expanding access to CART therapy via local institutions, Hadassah Medical Center experience. Poster Presentation, European Society for Bloos 37 and Marrow Transplantation and European Hematology Association 5th European CAR T-cell Meeting. 2023 Feb 9-11., Development and manufacturing of novel locally produced anti-BCMA CART cells for the treatment of relapsed/refractory multiple myeloma: phase I clinical results. Haematologica. 2022 Oct 6. doi: 10.3324/haematol.2022.281628. Epub ahead of print. PMID: 36200421., Note: SD = Stable Disease; PR = Partial Response; VGPR = Very Good Partial Response; SCR = stringent (10-5) Complete Response; CR = Complete Response#38IMX-110 MoA: Tissue-Specific Therapeutic™ with TME Normalization™ Technology www. wwwwww -PEG-PE -DOX - CUR ● www. www. www. 0 14-16nm diameter wwwww www. IgG Antibody: 10-15nm diameter BCL-X BCL2 -my urvivi PI3K AKT IMX-110 Upregulation in Cancer ¡MX-110 Downregulation. O O O O NFKB COX2 spase O Jak TAT3 ¡MX-110 DNA Damage ¡MX-110 Upregulation X iMX-110 Disperses Throughout Cell IMX-110 is a negatively-charged Tissue-Specific Therapeutic™M built on our TME Normalization™ Technology encapsulating a synergistic 5:1 ratio of poly-kinase inhibitor (polyphenol curcuminoid complex, or PCC) and apoptosis inducer (PEG-PE doxorubicin complex) delivered deep into the TME. First Oncology Micelle to achieve "small molecule penetration" Electrostatic charge attracts to tumor like a magnet Resulting in 1,200% increase in apoptosis (tumor cell death) vs. conventional therapies D Li (11) IMX-110 - Key Characteristics Get There: Deliver Payload Deep Into the Tumor Microenvironment Stay There: Accumulate in Tumors Kill Tumors: 12x Tumor Killing vs SoC 1% % of dose / g organ Control 10. (g) 8. 1 0 intensity (a.u.) →→→ 15% 600 200 -200 Free DOX -12nm -60nm -125nm 10 20 30 40 50 Time (h) ●●● IMMIX S BIOPHARMA 40 80 distance from vessel (μm)-> (Adapted from Popovic et al, 2010) Caspase 3/7 Increase (%) vs. Control (empty micelle) as an indicator of tumor apoptosis, after 24h -1,200% increase --181% penetration depth 35% Micellular DOX Free DOX 53% DOX micelles CUR micelles iMX-110 38 Source: Development and manufacturing of novel locally produced anti-BCMA CART cells for the treatment of relapsed/refractory multiple myeloma: phase I clinical results. Haematologica. 2022 Oct 6. doi: 10.3324/haematol. 2022.281628. Epub ahead of print. PMID: 36200421. Stan, S. D. et al. Nat. Rev. Gastroenterol. Hepatol. 7, 347-356 (2010); published online 4 May 2010. http://www.nature.com/doifinder/10.1038/nrgastro.2010.61. Popovic et al, A nanoparticle size series for in vivo fluorescence imaging. Angew Chem Int Ed Engl. 2010 Nov 8; 49(46): 8649-8652. https://dx.doi.org/10.1002%2Fanie.201003142; M Yokoyama, T Okano, Y Sakurai, S Fukushima, K Okamoto, K Kataoka. Selective delivery of adriamycin to a solid tumor using a polymeric micelle carrier system. https://doi.org/10.3109/10611869909085500; Sarisozen et. al. (2016- https://doi.org/10.1016/j.ejpb.2016.08.013).#39IMMX: Autoimmune CAR-T Company with 73 patients dosed to-date NXC-201 FDA Investigational New Drug (IND) Application Already Cleared 1 2 3 4 5 6 First CAR-T, NXC-201, in AL Amyloidosis Expanding into Additional Autoimmune indications First "single-day CRS" CAR-T NXC-201 n=73 patients across 11 peer-reviewed publications First CAR-T Overcoming Neurotoxicity IMX-110 - promising results in colorectal cancer with 30 patients dosed ● ● ● . ●●● IMMIX S BIOPHARMA 100% overall response rate in relapsed/refractory AL amyloidosis ($3bn market) No drugs approved in relapsed/refractory AL amyloidosis today (29,712 U.S. patient prevalence) BCMA CAR-Ts are not created equal: NXC-201 designed for high activity in AL Amyloidosis NXC-201 expanding into additional autoimmune indications - more than $25 bn combined annual market size NXC-201: first "single-day CRS" CAR-T (median day 1 onset) enables patients to return home 80% faster 95% overall response rate in relapsed/refractory multiple myeloma ($18bn market) 2 Presentations (1 Oral) at 2023 American Society of Hematology (ASH) 65th Meeting Mature dataset: American Society of Cell and Gene Therapy, Haematologica, other publications Precedents for open-label, single-arm FDA approvals at ~100 patient dataset - Carvykti, Abecma -10-20x potential increase in CAR-T addressable market through wider hospital availability -5x potential hospital per-bed revenue increase by reducing CAR-T hospitalization time Overcoming neurotoxicity allows expansion into: AL Amyloidosis, autoimmune, others 75% tumor shrinkage at 2 months in stage 4 MSS relapsed/refractory colorectal cancer ($27 billion market) 4 months median progression-free survival in soft tissue sarcoma ($3bn market), median 7 prior lines of therapy 39#40:: BIOPHARMA Appendix#41Outpatient Access To NXC-201 Potentially Increases CAR-T Addressable Market by 10-20x Today - CAR-T Treatment Options NXC-201 Treatment Options I I Today: CAR-T is accessible at only 5% I of US hospitals, mostly academic I research centers in major cities L CLINIC 00 CLINIC I DOOD I I + HOSPITAL 884 CLINIC +HOSPITAL 884 Future: NXC-201 potentially accessible at many more US hospitals, academic research centers in cities + regional medical centers and clinics -- ■ CLINIC 20 1000 + HOSPITAL +884 CLINIC 01 +HOSPITAL 884 I I I I CLINIC + HOSPITAL 188 BA CLINIC +HOSPITAL ■ CLINIC I ■ 000 ●●● IMMIX So BIOPHARMA +884 + HOSPITAL CLINIC 0 +HOSPITAL 88k CLINIC ■ Source: Sharma A, et al, Epidemiology and Predictors of 30-Day Readmission in CAR-T Cell Therapy Recipients. Transplant Cell Ther. 2023 Feb;29(2):108.e1-108.e7. doi: 10.1016/j.jtct.2022.11.004. Epub 2022 Nov 9. PMID: 36371048. George Washington University "The Differences Between Academic and Community Medical Centers"#42Ongoing Clinical Study Design Recommended Phase 2 Dose (RP2D) Already Determined at 800x10^6 150x10^6 CAR+ T cells (NEXICART-1/NCT04720313) in Multiple Myeloma N=6 450x10^6 CAR+ T cells N=7 As of September, 2023 800x10^6 CAR+ T cells N=50 ●●● IMMIX S BIOPHARMA RP2D already determined at at 800x10^6 50 patients in MM 9 in AL ►Dosing ongoing... Source: 8 patients treated in relapsed/refractory AL amyloidosis as of May 11, 2023, 5 at 800 x10^6 cells, 2 at 250 x10^6 cells, 1 at 150x10^6 cells. Multiple Myeloma data cutoff at February 9th, 2023. Lebel E, et al. Feasibility of a Novel Academic Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) (HBI0101) for the Treatment of Relapsed and Refractory AL Amyloidosis, International Myeloma Society 20th Annual Meeting. 2023. Lebel E, et al. Efficacy and Safety of a Locally Produced Novel Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) (HBI0101) for the Treatment of Relapsed and Refractory Multiple Myeloma, International Myeloma Society 20th Annual Meeting. 2023. 42#43Adverse Event Profile - NXC-201 Adverse Events Cytokine Release Syndrome (CRS) Day of median onset (min-max) Days of median duration (min-max) Immune cell associated Neurotoxicity (ICANS) Day of median onset (min-max) Day of median duration (min-max) Toxicity Management | Tocilizumab | Dexamethasone NXC-201 150x10 CAR+T cells n=6 Grade 3 0 (0%) 0 (0%) of n=6 1 (17%) 0 (0%) NXC-201 450x10 CAR+T cells n=7 Grade 3 0 (0%) 0 (0%) of n=7 4 (57%) 0 (0%) Grade 1-2 41 (82%) 1 2 (4%) NXC-201 800x10 CAR+T cells n=50 of n=50 40/48 (83%) 8/48 (17%) ●●● IMMIX S BIOPHARMA Grade 3 7 (14%) 2 0 (0%) Note. No Grade 4 CRS with NXC-201. Source: Development and manufacturing of novel locally produced anti-BCMA CART cells for the treatment of relapsed/refractory multiple myeloma: phase I clinical results. Haematologica. 2022 Oct 6. doi: 10.3324/haematol.2022.281628. Epub ahead of print. PMID: 36200421, Point-of-care CART manufacture and delivery: Expanding access to CART therapy via local institutions, Hadassah Medical Center experience. Poster Presentation, European Society for Blood and Marrow Transplantation and European Hematology Association 5th European CAR T-cell Meeting. 2023 Feb 9-11, Nexcella, Inc. E. Lebel et al. Efficacy and Safety of a Locally Produced Novel Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) (HBI0101) for the Treatment of Relapsed and Refractory Multiple Myeloma, International Myeloma Society 20th Annual Meeting. 2023. 43#44Adverse Event Profile - NXC-201 Market Adverse Events Cytokine Release Syndrome (CRS) Day of median onset (min-max) Days of median duration (min-max) Immune cell associated Neurotoxicity (ICANS) Day of median onset (min-max) Day of median duration (min-max) Toxicity Management Tocilizumab Dexamethasone Source: Arcellx July 2022 Corporate Presentation. ICANS of any grade ARCELLX 100 x10 cells n=25 Grade 3-4 0 (0%) 2 (1-8 days) 8 (3-13 days) 6 (24%) 4.5 (3-6 days) 7.5 (4-11 days) 19 (76%) 13 (52%) ARCELLX 300x10 cells n=6 Grade 3-4 1 (17%) 2 (1-2 days) 5 (3-10 days) 1 (17%) 7 days 23 days 5 (83%) 2 (33%) ●●● S BIOPHARMA IMMIX 44#45Preconditioning Regimens Lymphodepletion regimen Frequency Infusion (Day 0) from start of lymphodepletion (days) NXC-201 250 mg cyclophosphamide/m² + 25 mg fludarabine/m² QD, days -5, -4, -3 LO 5 Abecma 300 mg cyclophosphamide/m² + 30 mg fludarabine/m² QD, days -5, -4, -3 LO 5 Source: Berdeja JG, et al. Lancet. 2021; Frigault MJ, et al. Blood Adv. 2023; Munshi NC, et al. N Engl J Med. 2021; Asherie N, et al. Haematologica. 2023 Carvykti 300 mg cyclophosphamide/m² + 30 mg fludarabine/m² QD, days -5, -4, -3 5-7 ●●● IMMIX S BIOPHARMA CART-ddBCMA 300 mg cyclophosphamide/m² + 30 mg fludarabine/m² QD, days -5, -4, -3 LO 5 45#46Relapsed/Refractory Multiple Myeloma - Key Inclusion Criteria Prior lines of therapy Toxicity recovery ECOG Measurable disease NXC-201 (Ex-US Ph1/2 NCT04720313) >3 different prior lines of therapy including proteasome inhibitor, immunomodulatory therapy and >1 antibody therapy, refractory/responsive to the last line of therapy Recovery to ≤Grade 2 or baseline of any non-hematologic toxicities due to prior treatments, excluding alopecia and Grade 3 neuropathy . 0-2 Serum M-protein greater or equal to 0.5 g/dL Urine M-protein greater or equal to 200 mg/24 h Serum free light chain (FLC) assay: involved FLC level greater or equal to 5 mg/dL (50 mg/L) provided serum FLC ratio is abnormal Source: Clinical trials.gov; Asherie N, et al. Haematologica. 2023 >3 different prior lines of therapy including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 antibody, refractory to the last treatment regimen Abecma (pivotal NCT03361748) Recovery to Grade 1 or baseline of any non-hematologic toxicities due to prior treatments . . 0-1 Serum M-protein greater or equal to 1.0 g/dL Urine M-protein greater or equal to 200 mg/24 h Serum free light chain (FLC) assay: involved FLC level greater or equal to 10 mg/dL (100 mg/L) provided serum FLC ratio is abnormal Carvykti (pivotal NCT03548207) 23 different prior lines of therapy including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 antibody, refractory to the last treatment regimen, refractory or non-responsive to their most recent line of therapy . 0-1 Serum monoclonal paraprotein (M-protein) level more than or equal to (>=) 1.0 gram per deciliter (g/dL) Urine M-protein level >=200 milligram per 24 hours (mg/24hr) Light chain multiple myeloma without measurable disease in the serum or the urine: Serum immunoglobulin free light chain 10 mg/dL and abnormal serum immunoglobulin kappa lambda free light chain ratio ●●● S IMMIX BIOPHARMA CART-ddBCMA (pivotal NCT05396885) 23 different prior lines of therapy including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 antibody, refractory to the last treatment regimen Resolution of adverse events (AES) from any prior systemic anticancer therapy, radiotherapy, or surgery to Grade 1 or baseline 0-1 Serum M-protein 21.0 g/dL Urine M-protein 2200 mg/24 hours Involved serum free light chain ≥10 mg/dL with abnormal K/λ ratio (i.e., >4:1 or <1:2) 46#47Relapsed/Refractory Multiple Myeloma - Key Exclusion Criteria Prior BCMA therapy Prior cell therapy NXC-201 (Ex-US Ph1/2 NCT04720313) No exclusion Investigational cellular therapies within 8 weeks prior to the start of lymphodepletion Source: Clinical trials.gov; Asherie N, et al. Haematologica. 2023 Abecma (pivotal NCT03361748) BCMA targeted therapy Investigational cellular therapy for cancer Carvykti (pivotal NCT03548207) Have received any therapy that is targeted to B-cell maturation antigen (BCMA) Have received prior treatment with chimeric antigen receptor T (CAR-T) therapy directed at any target ●●● S IMMIX BIOPHARMA CART-ddBCMA (pivotal NCT05396885) Prior B-cell maturation antigen (BCMA) directed therapy Prior treatment with any gene therapy or gene-modified cellular immune-therapy 47#48TSTX Market Opportunity Annual Drug Sales (US$ billion) Company KeytrudaⓇ/ pembrolizumab MERCK $33.4bn combined OpdivoⓇ/ nivolumab Oncology (Soft tissue sarcoma, colorectal cancer) Bristol Myers Squibb AvastinⓇ/ bevacizumab Roche Cyramza Ⓡ/ ramucirumab Lilly $0.9bn combined VotrientⓇ/ pazopanib NOVARTIS ●●● IMMIX S BIOPHARMA Halaven Ⓡ/ YondelisⓇ/ eribulin trabectedin дад Eisai Source: Eisai FY2022 Financial Results Presentation, Novartis 2022 Annual Report, 2022 Merck Financial Results, 2022 Bristol Meyers Squibb Financial Results, Roche 2021 Investor Update, Eli Lilly 2022 Financial Results, Abbvie 2022 Financial Results, Johnson & Johnson 2022 Full Year Results, Takeda Annual Securities Report 48#49IMX-110 Preclinical Data Provides Translational Rationale & PD-1 Combination Rationale 50% 0% (50%) (100%) Percent Survival After One Cycle of Treatment At Day 22 75% IMX-110 Demonstrated Improved Survival iMX-110 IMX-110 Demonstrated Response Rate Better than Standard of Care Best % Change from Baseline in Size of Tumor +23% Trabectedin (sold as YONDELIS by Janssen, a Johnson & Johnson Company) 0% (41%) Standard of Care IMX-110 Treatment Treatment Group: Group: Responder Entire Group Mean (32%) • In a connective tissue cancer Soft Tissue Sarcoma (STS) mice study, IMX-110 was compared against approved drugs ¡MX-110 Treatment Group: Entire Group Mean • One cycle of IMX-110 produced 75% survival vs. 0% survival for Trabectedin (sold as YONDELIS ® by Janssen, a Johnson & Johnson Company, a U.S. FDA approved drug) May 20, 2022 Press Release • IMX-110 produced a 50% response rate after 1 cycle of treatment as a monotherapy in first-line- therapy-resistant cancer soft tissue sarcoma (STS) mice study • IMX-110 response rate surpassed standard of care doxorubicin's response rate of 0% after 1 cycle of treatment in the same study January 12, 2022 Press Release ● Median Survival In Genetic (KPC) Pancreatic Cancer Mouse Model IMX-110 +anti-PD-1 Potential Survival Benefit Better than Comparable Median Survival 63 days IMX-110 + anti-PD-1 IMMIX BIOPHARMA A50%! 05070 42 days 4-drug combination 2 chemotherapies (gemcitabine, nab-paclitaxel) and 2 immunotherapies (anti-PD-1, anti-CD40) Source: Inmix Biopharma, Inc. Adapted from Winograd, et al, 2015 January 25, 2022 10:15 ET | Source: Immix Biopharma, Inc. ●●● ● BIOPHARMA • IMX-110 + anti-PD-1 produced 63-day median survival in a genetic (KPC) pancreatic cancer mouse model in which mice develop their own pancreatic cancer and have an intact immune system ● Historically, 42-days is the median survival produced by a 4-drug combination of 2 chemotherapies and 2 immunotherapies in the same genetic pancreatic cancer mouse model according to Winograd et al., 2015 • 2022 plan to commence combination IMX- 110 + BeiGene anti-PD-1 tislelizumab Phase 1b/2a clinical trial in advanced solid tumors January 25, 2022 Press Release IMX-110 + anti-PD-1 Combination Produced Extended Median Survival in Genetic Pancreatic Cancer Mouse Model, Bolstering Planned 2022 IMX-110 Combination Clinical Trial Rationale 44 5#50Clinical Trial and Supply Agreement with BeiGene for Tislelizumab (Anti-PD-1 mAb) ● IMMIX ΒΙΟΡΗΑR ΜΑ Study Goal Demonstrate the potential for TSTX to be an integral component of combination therapies for a wide range of advanced solid tumors Rapid IMX-110 expansion into additional oncology indications By eliminating immunosuppressive T-regulatory immune cells IMX-110 ● MAN Combination Trial Design ¡MX-110 + tislelizumab (anti-PD-1) BeiGene 30 patient Phase 1b study across advanced solid tumors enabling cytotoxic T- lymphocytes to enter the tumor of Scientific Basis: IMX-110 turns “cold” tumors “hot” in genetic (KPC) mouse models of pancreatic cancer IMX-110 + murine anti-PD-1 survival exceeded by exactly 50% a 4-drug combination (anti-PD-1/anti-CD40/nab-paclitaxel/gemcitabine) in a genetic pancreatic cancer (KPC) mouse model in the literature ●●● S ¡MX-110 Joint Alliance Committee IMMIX BIOPHARMA A Joint Alliance Committee consisting of members from ImmixBio & BeiGene will coordinate the clinical trial and eliminating tumor vascularization. As of June 2021, in China, tislelizumab has already been approved or granted conditional approved in 5 cancer indications, including non-squamous non- small cell lung cancer ("NSCLC"), squamous NSCLC, classical Hodgkin's lymphoma, Hepatocellular Carcinoma, and urothelial carcinoma (Source: BeiGene Businesswire Press Release "China NMPA Approves Tislelizumab in Non-Small Cell Lung Cancer and Hepatocellular Carcinoma" Dated Jun 23, 2021) iMX-110 50#51iMX-110 Pancreatic Preclinical KPC Mouse Model: (iMX-110 + PD-1) Outperforms (Gem + Pac + PD-1 + CD-40) Median Survival Comparison | Pdx1-Cre (KPC mice) Panc Model mOS (Days) IMMIX IMX-110 + PD-1 Perelman SCHOOL OF MEDIMINE Usestry of PENYANA CD40/G/NP + PD-1 63 1 450% 42 IMMIX Immix Biopharma Unpublished Data KPC Mice Survival (90 Days) 120 Dosing Schedule IMX-110 aPD-1 80 40 0 120 80 40 Dosing Schedule Gemcitabine (G) nab-Paclitaxel (np) aPD-1 aCD40 0 0 Pancreatic Pdx1-Cre (KPC mice) Model - ¡MX-110 + PD-1 Combination 4 ▲▲▲▲▲ A A A T 8 12 16 20 24 28 32 36 40 44 48 52 56 60 64 68 72 76 80 84 88 92 96 100 Days from Enrollment A Perelman Winograd et al; Cancer Immunol Res. 2015 Apr;3(4):399-411. UTY of PANTA KPC Mice Survival (90 Days) AAAAA A ▲ A AAAAA A A A IMX-110 + PD-1 (n=3) Isotype Alone (n=6-8) CD40/G/nP (n=6-8) 0 4 8 12 16 20 24 28 32 36 40 44 48 52 56 60 64 68 72 76 80 84 88 92 96 100 Days from Enrollment Source/Adapted from: Immix Biopharma, Inc. Winograd et al. Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma. Cancer Immunol Res..2015 Apr;3(4):399-411. doi: 10.1158/2326-6066.CIR-14-0215. Epub 2015 Feb 12. Immix Biopharma Dosing: IMX-110 dosed based on doxorubicin at 1.5 mg/kg, aPD-1 (RMP1-14; BioXcell) 100µg/dose Winograd, et al Dosing: gemcitabine (Eli Lilly) 120 mg/kg, nab-paclitaxel (Sigma) 108 mg/kg, aCD40 (FGK45; BioXcell) 100μg/dose, aPD-1 (RMP1-14; BioXcell) 200µg/dose PD-1 alone (n=6-8) CD40/G/nP+ PD-1 (n=6-8) Individual Mice - Luciferase activity (tumor growth) activity Mouse A 1663 (pdx1-Cre) ●●● IMMİX S BIOPHARMA ¡MX-110 + PD-1 Mouse B 1689 (p48-Cre) Perelman SCHOOL OF MEDICINE ¡MX-110 + PD-1 IMMIX IMX-110 (n=3) Tumor Frequency All Mice 100% 100% 51#52IMX-110 1b/2a Data: Tumor Shrinkage in 75% of Heavily Pretreated Soft Tissue Sarcoma Patients | | I I % Change in Target Lesion Size from Baseline Week 16 Week 24 100% 80% 60% 20% 40% Progressive Disease (PD) Threshold 0% Soft Tissue Sarcoma | iMX-110 Monotherapy Baseline ¡MX-110 (20%) I (40%) Partial Response (PR) Threshold | (60%) I (80%) | (100%) I Week 8 2 Month PFS 5th line therapy 4 Month PFS 9th line therapy 4 Month PFS (6 month radiological PFS) 4th line therapy 6 Month PFS 14th line therapy 31cm tumor diameter across 5 target lesions Patient Indication | Dose Soft Tissue Sarcoma | 8.4 -Soft Tissue Sarcoma | 10.4 Soft Tissue Sarcoma | 10.4 Soft Tissue Sarcoma | 9.6 Best % Change from Baseline in Size of Target Lesions 26% -10% -17% -18% Dosing Schedule- | 100% Non-Sarcoma Cancers | iMX-110 Monotherapy 80% 60% 40% 20% 0% (20%) % Change in Target Lesion Size from Baseline Baseline Week 8 Week 16 Week 24 Week 32 Compassionate Use PD Threshold 4 Month PFS Colorectal 14th line therapy iMX-110 PD Threshold (40%) PR Threshold (60%) (80%) (100%) ●●● S E IMMIX BIOPHARMA PR Threshold - Colorectal | 5.0 Wk 40 Patient Indication | Dose Nasopharyngeal | 3.4 Colorectal | 5.0 Breast 10.4 Colorectal | 1.4 Source: Immix Biopharma, Inc. ImmixBio has evaluable data for the 8 patients as of October 2021 (out of n=15, 6 did not complete any tumor measurements after enrolment scan, 1 was dosed in Dec 2022). All 8 evaluable patients have discontinued treatment. "Heavily Pretreated" refers to 3-13 lines of therapy. Dose on far right for each patient expressed in mg/m². 52#53IMX-110 Opportunity: Soft Tissue Sarcoma - Remains An Unmet Medical Need Select Approved Therapies & Clinical Trials in Soft Tissue Sarcoma mPFS (months) 5 4 3 2 1 0 -20% Judson DOX 14 Chawla DOX '15 Lorigan DOX '07 0% ران gsk Pazopanib NOVARTIS 20% MERCK Pembrolizumab Bristol Myers Squibb Nivolumab + Ipilimumab 40% Eisai Eribulin Bristol Myers Squibb Nivolumab 60% 80% 100% STS Sub-Indication Drugs Used To Treat Soft Tissue Sarcoma Leiomyosarcoma Liposarcoma Undifferentiated Pleomorphic Sarcoma (Adapted From In et al, 2017) Disease Control @ 2 mos Median Progression Free Survival Dose Interruptions due to Toxicity Drug-Related SAEs Overall Response Rate % Of Patients With ≥ 3 Lines Of Treatment Prior to Therapy Note: mPFS is Median Progression Free Survival Dollar amounts are annual drug sales. Adapted from: Lorigan et al. Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol. 2007 Jul 20:25(21):3144-50. doi: 10.1200/JCO.2006.09.7717. Judson et al. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. Lancet Oncol. 2014 Apr;15(4):415-23. doi: 10.1016/S1470- 2045(14)70063-4. Chawla et al. First-Line Aldoxorubicin vs Doxorubicin in Metastatic or Locally Advanced Unresectable Soft-Tissue Sarcoma: A Phase 2b Randomized Clinical Trial. JAMA Oncol. 2015 Dec;1(9):1272-80. doi: 10.1001/jamaoncol 2015.3101. Tawbi et al. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol. 2017 Nov;18(11):1493-1501, doi: 10.1016/S1470-2045(17)30624-1. D'Angelo et al. Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials. Lancet Oncol. 2018 Mar:19(3):416-426. doi: 10.1016/S1470-2045(18)30006-8. Schöffski et al. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. Lancet. 2016 Apr 16,387(10028):1629-37. doi: 10.1016/S0140-6736(15)01283-0. D'Angelo et al. Pilot study of NKTR214 and nivolumab in patients with sarcomas. Journal of Clinical Oncology 2019 37:15_suppl, 11010-11010. DOI: 10.1200/JC0.2019.37.15 suppl 11010. van der Graaf et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2012 May 19,379(9829):1879-86. doi: 10.1016/S0140-6736(12)60651-5. Epub 2012 May 16. 1st Line single-agent doxorubicin (generic) doxorubicin and ifosfamide (generic) liposomal doxorubicin (generic, 1995 JJ) 68% 2.7 months ? 18% 0% Doxorubicin (Chawla et al, 2015) 2nd Line Gemcitabine docetaxel (generic) Trabectedin (2015) Gemcitabine + docetaxel (generic) 62% 4.2 months 57% 13% ●●● S 10% (0% CR) Trabectedin. (Demetri et al, 2015) IMMIX BIOPHARMA 3rd Line Trabectedin (2015) Eribulin (2010) Pazopanib (2009) 58% 2.6 months 33% 8% 4% (0% CR) Eribulin (Schöffski et al, 2016) Note: CR is Complete Response. Adapted from: Chawla et al. First-Line Aldoxorubicin vs Doxorubicin in Metastatic or Locally Advanced Unresectable Soft-Tissue Sarcoma: A Phase 2b Randomized Clinical Trial. JAMA Oncol. 2015 Dec;1(9):1272-80. doi: 10.1001/jamaoncol.2015.3101. Demetri et al, Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial. J Clin Oncol. 2016 Mar 10;34(8):786-93. doi: 10.1200/3CO.2015.62.4734. Epub 2015 Sep 14. Schöffski et al. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. Lancet. 2016 Apr 16:387(10028):1629-37. doi: 10.1016/S0140-6736(15)01283-0. In et al, Treatment of advanced, metastatic soft tissue sarcoma: latest evidence and clinical considerations. Ther Adv Med Oncol. 2017 Aug;9(8):533-550. doi: 10.1177/1758834017712963. Epub 2017 Jun 15. 53#54IMX-110 Clinical Data: 4-month mPFS in Late Stage Sarcoma, Well Tolerated IMX-110 Median Progression Free Survival in Late Stage STS mPFS (months) 5 4 months 3 2 1 0 0% (note: IMMIX n=4) 20% 40% 60% IMMIX ¡MX-110 4 month mPFS across 100% heavily pre-treated soft tissue sarcoma patients 80% % Of Patients With ≥ 3 Lines Of Treatment Prior to Therapy 100% STS Sub-Indication Leiomyosarcoma Liposarcoma Undifferentiated Pleomorphic Sarcoma ImmixBio iMX-110 Clinical Trial Disease Control @ 2 mos Median Progression Free Survival Dose Interruptions due to Toxicity Drug-Related SAEs Overall Response Rate Median 7th Line (4-14th Line) IMMIX iMX-110 100% 4 months 0% 0% 0% iMX-110 (ImmixBio Unpublished) ●●● IMMIX S BIOPHARMA 14th Line Patient IMMIX ¡MX-110 100% 6 months 0% 0% 0% ¡MX-110 (ImmixBio Unpublished) 54#55IMX-110: Direct Path To 1st Line Therapy in STS - Clinical Trial Plan ¡MX-110 Monotherapy ¡MX-110 + tislelizumab (anti-PD-1) combination Phase 1b iMX-110 Ongoing Phase 2a iMX-110 30 patients End of Phase 2a Phase 1b iMX-110 + tislelizumab (anti-PD-1) 30 patients BeiGene Trial Relapsed/refractory advanced solid tumors 1st Line Therapy Advanced STS Relapsed/refractory advanced solid tumors ¡MX-110 Establish MTD / RP2D iMX-110 at RP2D iMX-110 + tislelizumab Establish MTD / RP2D & NOVARTIS ●●● S IMMİX BIOPHARMA Status Ongoing Ongoing 55#56IMX-111: GLUT1 Biomarker-targeted for Colorectal Cancer iMX-111 is a Tissue-Specific Biologic™ built on our TME Normalization™ Technology with proprietary GLUT1 antibody biomarker targeting facilitating preferential accumulation in glucose-consuming cancer cells such as colorectal cancer. ImmixBio Proprietary GLUT-1 scFv antibody www. wwww.. -PEG-PE =DOX =CUR wwwww www. ¡MX-111 www. www. www. www wwwww www. www 17-23nm diameter IgG Antibody: 10-15nm diameter 01 ¡MX-111's GLUT1 target is overexpressed on Colorectal and other cancers 02 GLUT1 is associated with poor prognosis in colorectal cancer 03 100% survival @ 24 days vs. 0% control survival in colorectal cancer xenograft model Percentage of tumors with increased GLUT1 expression compared to non-tumorous tissue (Adapted from Amann, 2009) % Survival I+II Overexpression of GLUT1 Associated With Stage 3/4 Colorectal Cancer (Shen, 2011) 100 80 60 40 20 Dosing Schedule ¡MX-111 0 0 2 III+IV 4 A 6 A Brain (glia cell) Esophagus Colon/rectum 8 Ovarian Stomach Bile duct Lung A Endometrium Breast Colorectal Cancer Stage Relative Value of GLUT1 Expression in colorectal cancer PBS - Control 10 12 14 16 A Healthy Normal Colon No/ Light GLUT1 Staining HCT-116 CRC Xenograft Model: Survival Curve 18 ●●● IMMİX S BIOPHARMA (Adapted from Haber, 1998) ¡MX-111 72% 71% 3 92% 86% 86% 81% 76% 100% 100% Source: Adapted from Abouzeid, et. al. Anti-cancer activity of anti-GLUT1 antibody targeted polymeric micelles co-loaded with curcumin and doxorubicin (2013 - https://doi.org/10.3109/1061186x.2013.840639); Shen, et al. Overexpression of GLUT1 in colorectal cancer is independently associated with poor prognosis. Int J Biol Markers. Jul-Sep 2011;26(3):166-72. doi: 10.5301/JBM.2011.8550. Epub 2011 Jul 22. Amman, et al. GLUT1 as a therapeutic target in hepatocellular carcinoma. Expert Opin Ther Targets. 2009 Dec;13(12):1411-27. doi: 10.1517/14728220903307509; Haber, et al. GLUT1 Glucose Transporter Expression in Colorectal Carcinoma: A Marker for Poor Prognosis. Cancer. 1998 Jul 1;83(1):34-40. doi: 10.1002/(sici)1097-0142(19980701)83:1<34::aid- cncr5>3.0.co;2-e. Colorectal Carcinoma Heavy GLUT1 Staining 20 22 24 26 28 30 32 34 36 38 40 42 Days After Initial Treatment (Adapted from Abouzeid et al, 2013) 56#57iMX-111 Preclinical Data in TNBC Breast & Colorectal Cancer: Immix Biopharma Therapies Produce Rare Tumor Shrinkage/Stability Effective in Doxorubicin resistant MDA-MB-231 TNBC Breast Cancer Cell Line... Dosing Schedule ¡MX-110 250 200 150 100 50 0 MDA-MB-231 Xenograft Model: Tumor Volume after 7 injections PBS Control Dosing Stop I I I GLUT1-CUR+DOX Micelles 12 14 16 18 20 22 24 26 28 30 32 34 36 38 40 42 44 46 48 50 52 ▲▲▲▲▲▲ iMX-111 Tumor inhibition studies of various micellar formulations. Nude mice bearing -150 mm³ MDA-MB-231 tumors were treated every 2 days starting at Day 20 except last injection administered at day 33 (7 total IV injections) at a dose of 6 mg/kg CUR and 1 mg/kg DOX. N26 with SEM (Adapted from Abouzeid et al, 2014). . And Effective in HCT-116 Colorectal Cancer Cell Line Which Is Not Typically Treated With Doxorubicin 1400 1200 1000 800 600 400 200 0 Dosing Schedule iMX-110 100 80 60 40 20 0 Dosing Schedule iMX-110 HCT-116 Xenograft Model: Tumor Volume & Survival Curve after 14 day treatment (7 injections) 0 2 0 2 A A 4 4 6 6 A 8 A 8 A -PBS - Control Dosing Stop I 10 12 | 1 14 16 18 20 10 12 14 A 16 18 20 T 22 GLUT1-CUR+DOX Micelles + I 22 24 26 24 26 ¡MX-111 ●●● IMMİX S BIOPHARMA Days After Initial Treatment 28 30 32 34 36 38 40 42 Adapted from: Abouzeid, et. al. Anti-cancer activity of anti-GLUT1 antibody targeted polymeric micelles co-loaded with curcumin and doxorubicin (2013 - https://doi.org/10.3109/1061186x.2013.840639); Abouzeid et al, Nanotechnology-based treatment for chemotherapy-resistant breast cancer. SPIE 9166, Biosensing and Nanomedicine VII, 916606 (27 August 2014); doi: 10.1117/12.2064660. Measurements + SD. ¡MX-111 Days After Initial Treatment Tumor inhibition studies of various micellar formulations. Female nude (NU/NU) mice bearing 250mm³ HCT-116 tumors were treated every 2 d starting at day 0 (7 total tail vein injections, arrows correspond to injection days) at a dose of 4 mg/kg CUR and 0.4 mg/kg DOX. N = 6 with SEM. Empty micelle dose was equivalent to the amount of lipid from the drug-loaded micelle groups. A - Tumor volume. B- Survival curve, survival was determined when the tumor reached 1000mm³ (Adapted from Abouzeid et al, 2013) 57#58IMX-120 GLUT1 Biomarker-targeted for Inflammatory Bowel Disease iMX-120 is a Tissue-Specific BiologicTM with Immune Normalization Technology encapsulating anti- inflammatory poly-kinase inhibitors (polyphenols) with proprietary targeting (GLUT1/ confidential targets) selectively silencing disease-causing inflammatory bowel immune cells. iMX-120 confider GLUTF1 scFv www. w -PEG-PE Effector molecules www ww www. www. www. www www. 17-23nm diameter "fistulas are a very disabling manifestation and source of morbidity for Crohn's disease (CD) patients...the cumulative incidence of perianal fistulas in CD range from 23% to 38% ... treatment of perianal CD requires a combined surgical and medical approach" (Adapted from Marzo et al, 2015) 01 iMX-120 effector polyphenols have shown promise in IBD clinical studies 02 GLUT1/ confidential targeting, selectively silencing disease-causing IBD immune cells ■Curcumin + Mesalamine ("Curcumin") 65% Glucose Ulcerative Colitis Oral Curcumin + SOC Produced Responses & Remissions Far Exceeding SOC Alone (n=50) Response wk 4 (Adapted from Lang et al, 2015). Glut1 Lactate 13% 54% 0% Remission wk 4 Glycolytic-M1 GLYCOLYSIS (mTOR, HIF-1a) -ATP مملوك مول تلك iMX-120 targeting halts pro-inflammatory immune effects ROS ATP Glutamine GLUTAMINOLYSIS Mesalamine Alone ("Placebo") Gut 58 epithelium ‒‒‒‒‒‒‒‒ 45% Endoscopic response wk 4 Pro-inflammatory cytokines, lipids & metabolites 0% Glycolytic EVS ROS-HIF-1a HIV CD4 T cell Glucose 2 Recruited Warburg-like monocytes and T cells Model showing potential inflammatory and immunometabolic consequences of gut barrier dysfunction (Adapted from Alzahrani et al, 2019) 36% 0% Endoscopic remission wk 4 Knockout - I Glutl Teff AI Crohn's Disease Oral Curcumin vs Placebo Produced Remissions (n=30) (Adapted from Sugimoto et al, 2020) Wild-Type CD4 1 TBD GVHD - Theracurmin 35% GLUT1 inhibition significantly reduces IBD/ bowel inflammation in mouse models naive ●●● S Treg 4 week clinical remission rate Glucose (Adapted from Macintyre. et al, 2014) Glycolysis 4 MTOR Growth Proliferation Teff function IMMIX BIOPHARMA Inhibition 0% Inflammation score Placebo +4 PBS m-CPPD MSU PBS IGLUT1 10mg/kg Source: Adapted from Marzo et al, Management of perianal fistulas in Crohn's disease: An up to-date review. World J Gastroenterol. 2015 Feb 7; 21(5): 1394-1403. doi: 10.3748/wjg.v21.15.1394; Lang et al, Curcumin in Combination With Mesalamine Induces Remission in Patients With Mild-to-Moderate Ulcerative Colitis in a Randomized Controlled Trial. Clin Gastroenterol Hepatol. 2015 Aug;13(8):1444-9.e1. doi: 10.1016/j.cgh.2015.02.019. Epub 2015 Feb 24; Sugimoto et al, Highly Bioavailable Curcumin Derivative Ameliorates Crohn's Disease Symptoms: A Randomized, Double-Blind, Multicenter Study. J Crohns Colitis. 2020 May 15. doi: 10.1093/ecco-jcc/jjaa097; Alzahrani et al, Inflammatory and immunometabolic consequences of gut dysfunction in HIV: Parallels with IBD and implications for reservoir persistence andnon-AIDS comorbidities. Lancet EBioMedicine. 2019 Aug;46:522-531. doi: 10.1016/j.ebiom.2019.07.027; Renaudin et al, Gout and pseudo-gout-related crystals promote GLUT1-mediated glycolysis that governs NLRP3 and interleukin-18 activation on macrophages. Ann Rheum Dis. 2020 Nov;79(11):1506-1514. doi: 10.1136/annrheumdis-2020-217342. Epub 2020 Jul 22; Macintyre et al, The Glucose Transporter Glut1 Is Selectively Essential for CD4 T Cell Activation and Effector Function. Cell Metab. 2014 Jul 1;20(1):61-72. doi: 10.1016/j.cmet.2014.05.004. Epub 2014 Jun 12. ..Hei: (Adapted from Renaudin et al, 2020) 58#59IMX-120 Opportunity: Inflammatory Bowel Disease (IBD) Market Treatment Arm Placebo Company Clinical Remission Rate at Wk 8 Moderate-to-severe ulcerative colitis (who received concurrent treatment with oral corticosteroids or immunosuppressants) 16.5% 9.3% Humira®/adalimumab vs. placebo abbvie Sources: Adapted from Sandborn et al., 2012, Sands et al., 2019, FDA Entyvio® Prescribing Label Clinical Remission Rate at Wk 8 Moderate-to-severe ulcerative colitis 15.6% 5.3% Stelara/ustekinumab vs. placebo Johnson & Johnson ●●● IMMİX S BIOPHARMA Clinical Remission Rate at Wk 6 Moderately to severely active ulcerative colitis 17% 5% Entyvio/vedolizumab vs. placebo Takeda 59#60N-GENIUS Platform + IMMIXBio™ SMARXT Tissue-Specific™ Platform HIM N-GENIUS PLATFORM 3 Key Elements Purpose-Built Cell Therapy Evidence Capture Engine + Relational Database Relating ImmixBio internal data to external to accelerate therapy design, manufacture, and preclinical Proprietary EXPAND technology Applied to multiple cell therapy indications, already utilized to create NXC-201, to potentially increase efficacy and tolerability Atomized, Novel Binding Scaffold Generation Engine Allows us to make the correct binding for every molecule Source: Development and manufacturing of novel locally produced anti-BCMA CART cells for the treatment of relapsed/refractory multiple myeloma: phase I clinical results. Haematologica. 2022 Oct 6. doi: 10.3324/haematol.2022.281628. Epub ahead of print. PMID: 36200421. TME Normalization™ Technology - SMART Tissue-Specific Platform Oncology Application 3 Pillars Benefit 1 2 ●●● IMMIX S BIOPHARMA 3 System-Tissue Biology Model Development Purpose-Built Physical Biochemistry Engine Predictive Validation Framework Robust MOAS in Complex Pathologies Generate Actionable Drug Candidates Highly Predictive IND-Enabling Activities 60#61Cell Therapy Platform HIM 3 Key Elements Purpose-Built Cell Therapy Evidence Capture Engine + Relational Database Relating ImmixBio internal data to external to accelerate therapy design, manufacture, and preclinical Proprietary EXPAND technology Applied to multiple cell therapy indications, already utilized to create NXC-201, to potentially increase efficacy and tolerability Atomized, Novel Binding Scaffold Generation Engine Allows us to make the correct binding for every molecule N-GENIUS PLATFORM NXC-201 CAR-T CELL NXC-301 CAR-T CELL BCMA EXPRESSING CANCER CELL NXC-401 CAR-T CELL NXC-201 CAR-T CELL CANCER CELL NXC-301 CAR-T CELL CANCER CELL Source: Development and manufacturing of novel locally produced anti-BCMA CART cells for the treatment of relapsed/refractory multiple myeloma: phase I clinical results. Haematologica. 2022 Oct 6. doi: 10.3324/haematol.2022.281628. Epub ahead of print. PMID: 36200421. Lebel E, et al. Efficacy and Safety of a Locally Produced Novel Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) (HBI0101) for the Treatment of Relapsed and Refractory Multiple Myeloma, International Myeloma Society 20th Annual Meeting. 2023. NXC-401 CAR-T CELL Produced NXC-201, NXC-301, NXC-401 BCMA Surface Expression 1 NXC-201 BCMA I Chimeric Antigen Receptor I (CAR) I I Surface Expression I. NXC-301 I Proprietary Chimeric I Antigen Receptor I (CAR) I I Surface Expression. NXC-401 Proprietary I Chimeric Antigen Receptor I (CAR) ● NXC-201 is a next-generation chimeric antigen receptor (CAR) T-cell (CAR-T) targeting B-cell maturation antigen (BCMA) ● ● ●●● IMMİX S BIOPHARMA NXC-301 is a next-generation CAR-T with a proprietary target. Indications: High Complete Response Rates in AL Amyloidosis and Multiple Myeloma ● First Outpatient CAR-T: Short CRS duration (median 1 day) starting on day 0 4% neurotoxicity Acute lymphocytic leukemia (ALL) Large B-Cell Lymphoma (LBCL) Mantle cell lymphoma (MCL) NXC-401 is a next-generation CAR-T with a proprietary target. Indications: Acute Myeloid Leukemia (AML) 61#62N-GENIUS Platform Process 1. Problem Identification: CAR-T Toxicity Main Block To Widespread Use: Neurotoxicity 10. NXC-201 4-188 CD3 2. Research Group Formation: Reduce CAR-T Toxicity While Improving Efficacy Day-1 Day +3 Day +7 9. Evaluation CAR-T activity in vivo (tumor growth, cytokine release, safety evaluation) Day +11 Day +14 Day +20 Day +28 Day +56 Day +76 NT Mouse 1 Mouse 2 NT Mouse 3 Mouse 4 Source:: Harush O, et al. Haematologica. 2022; Tumor 1.04g 171g 1.50 HBBB 5x10 za HBBB 10x10 H8BB 15x105 3. Platform Foundation: N- GENIUS Platform with EXPAND Technology aims to achieve research group goal NEXCELLA NEXT GENERATION CELL THERAPIES 8. Co-culture of CAR-T cells and target cells with target antigens and in vitro analysis of cytokine release www. 4. Candidate Creation: Entire CAR- T construct optimized with N- GENIUS Platform and EXPAND Technology In Selected Indications 7. CAR-T Transgene expression was assessed by flow cytometry % of Max 0 10³ CAR NGFR, APC 67% 62% 40% 41% T™ 10* H8BB 5. Final Candidate Selection: 4 promising candidates selected among a larger number of options H828 ICBB IC28 ●●● S Anti BCMA scFv Anti BCMA scFv Anti BCMA scFv Anti BCMA scFv Blood collection (cukapheress) IMMİX BIOPHARMA CD8a CD8a hinge TM CD8a hinge CD8a TM IgG4 CD28 hinge TM IgG4 CD28 hinge TM Continuous flow centrifugation 41BB CD28 Retum unneeded blood components 41BB CD28 Manarucles cels CD3 6. Human Peripheral blood mononuclear cells (PBMC) were transduced with the CAR candidates CD3 CD3 CD3 Plack por plasma Endalend cells and granulocytes Isalate PBMC fraction 62#63IMMIXBIO™ SMARXT Tissue-Specific™ Platform Oo FIM TME Normalization™ Technology – SMARXT Tissue-Specific Platform Oncology Application 3 Pillars System-Tissue Biology Model Development Purpose-Built Physical Biochemistry Engine Predictive Validation Framework IMX-110 IMX-111 BIOLOGIC IMX-120 BIOLOGIC www. UT-1 SCFV GLUT-1 scFv 8 wwww Effector molecules Produced IMX-110, IMX-111, IMX-120 AWA www -PEG-PE -DOX -CUR www. ww www. -PEG-PE -DOX -CUR NO DO -PEG-PE www O ∞ www www- O ●●● S BIOPHARMA IMMİX is a negatively-charged Tissue-Specific Therapeutic™M built on our TME NormalizationTM Technology encapsulating a synergistic 5:1 ratio of poly-kinase inhibitor and apoptosis inducer delivered deep into the TME First Oncology Micelle to achieve "small molecule penetration Electrostatic charge attracts to tumor like a magnet ● Resulting in 1,200% increase in apoptosis (tumor cell death) vs. conventional therapies is a Tissue-Specific Biologic™ built on our TME Normalization™ Technology with proprietary GLUT1 antibody biomarker targeting facilitating preferential accumulation in glucose-consuming cancer cells. Indication: Colorectal Cancer (CRC) is a Tissue-Specific Biologic™M with Immune Normalization Technology encapsulating anti-inflammatory poly-kinase inhibitors (polyphenols) with proprietary targeting (GLUT1/ confidential targets) selectively silencing disease- causing inflammatory bowel immune cells. 63#64:: BIOPHARMA The Art of Precision, The Science of Cure Pioneering personalized therapies for oncology and immunology DECEMBER 2023 NASDAQ:IMMX